Nicotine salt, co-crystal and salt co-crystal composites
Nicotine salts and co-crystals are developed to address the handling challenges of high-nicotine extracts, offering improved stability and solubility for incorporation into tobacco products.
Patent Information
- Application Number
- JP2024107228
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2014-05-27
- Filing Date
- 2024-07-03
- Publication Date
- 2024-11-06
AI Technical Summary
Nicotine extracts with high proportions of nicotine, typically in oil form, are difficult to handle and incorporate into tobacco products effectively.
Development of nicotine salts, co-crystals, and salt co-crystals that are easier to handle and incorporate into tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles, through the preparation of specific nicotine salts and polymorphic forms.
The nicotine salts and co-crystals provide improved handling, thermal stability, and increased solubility, allowing for efficient incorporation into a variety of products, enhancing their usability and stability.
Smart Images

Figure 2024156667000027 
Figure 2024156667000028 
Figure 2024156667000029
Abstract
Description
[Technical field]
[0001] The present invention relates to various salts, co-crystals, and salt co-crystals of nicotine, as well as compositions and products (e.g., tobacco products) into which such salts, co-crystals, and salt co-crystals may be incorporated. [Background technology]
[0002] Cigarettes, cigars, and pipes are popular smoking articles that use tobacco in various forms. Such smoking articles are used by heating or burning tobacco, and the aerosol (e.g., smoke) is inhaled by the smoker. Electronic smoking articles are a further type of tobacco product, and include a reservoir and a heating system for the delivery of aerosolizable material. Tobacco may also be enjoyed in a so-called "smokeless" form. Particularly popular smokeless tobacco products are used by inserting some form of processed tobacco or tobacco-containing formulation into the user's mouth.
[0003] Various types of cigarette components, including tobacco types, tobacco blends, top dressing and casing materials, blend packing densities and types of wrapping materials for tobacco rods, have been described in the art. For example, various representative types of cigarette components, as well as various cigarette designs, formats, configurations and characteristics, are described in Johnson, Development of Cigarette Components to Meet Industry Needs, 52 ndNo. 5,101,839 (Jakob et al.), U.S. Pat. No. 5,159,944 (Arzonico et al.), U.S. Pat. No. 5,220,930 (Gentry), and U.S. Pat. No. 6,779,530 (Kraker), U.S. Patent Application Publication Nos. 2005 / 0016556 (Ashcraft et al.), 2005 / 0066986 (Nestor et al.), 2005 / 0076929 (Fitzgerald et al.), 2006 / 0272655 (Thomas et al.), 2007 / 0056600 (Coleman, III et al.), and 2007 / 0246055 (Oglesby), each of which is incorporated herein by reference.
[0004] Exemplary smokeless tobacco formulations, ingredients, and processing methods are described in U.S. Pat. Nos. 1,376,586 (Schwartz), 3,696,917 (Levi), 4,513,756 (Pittman et al.), 4,528,993 (Sensabaugh, Jr. et al.), 4,624,269 (Story et al.), 4,991,599 (Tibbetts), 4,987,907 (Townsend), 5,092,352 (Spring et al.), and 5,102,111 (Smith et al.). Nos. 5,387,416 (White et al.), 6,668,839 (Williams), 6,834,654 (Williams), 6,953,040 (Atchley et al.), 7,032,601 (Atchley et al.), and 7,694,686 (Atchley et al.); U.S. Patent Publication Nos. 2004 / 0020503 (Williams) and 2005 / 0115580 (Quinter et al.). , 2006 / 0191548 (Strickland et al.), 2007 / 0062549 (Holton, Jr. et al.), 2007 / 0186941 (Holton, Jr. et al.), 2007 / 0186942 (Strickland et al.), 2008 / 0029110 (Dube et al.), 2008 / 0029116 (Robinson et al.), 2008 / 0173317 (Robinson et al.), 2008 / 0196 No. 730 (Engstrom et al.), No. 2008 / 0209586 (Neilsen et al.), No. 2008 / 0305216 (Crawford et al.), No. 2009 / 0065013 (Essen et al.), No. 2009 / 0293889 (Kumar et al.), No. 2010 / 0291245 (Gao et al.), and No. 2011 / 0139164 (Mua et al.), PCT Publication Nos. WO 04 / 095959 (Arnarp et al.), and WO 2010 / 132444 A2 (Atchley), each of which is incorporated herein by reference.Exemplary commercially available smokeless tobacco products include those referred to as CAMEL Snus, CAMEL Orbs, CAMEL Strips, and CAMEL Sticks by RJ Reynolds Tobacco Company; GRIZZLY moist tobacco, KODIAK moist tobacco, LEVI GARRETT loose tobacco, and TAYLOR'S PRIDE loose tobacco by American Snuff Company, LLC; KAYAK moist snuff and CHATTANOOGA CHEW chewing tobacco by Swisher International, Inc.; REDMAN chewing tobacco by Pinkerton Tobacco Co. LP; COPENHAGEN moist tobacco, COPENHAGEN Pouches, SKOAL Bandits, SKOAL Pouches, RED SEAL long cut, and REVEL mint tobacco packs by USS Smokeless Tobacco Company; and MARLBORO Snus and Tobacco by Philip Morris USA.
[0005] Many smoking devices have been proposed over the years as an improvement or alternative to smoking products that require the burning of tobacco for use. Many of these devices are intentionally designed to provide the sensation associated with cigarette, cigar, or pipe smoking without delivering significant amounts of incomplete combustion and pyrolysis products resulting from the burning of tobacco. To this end, numerous smoking products, flavor generators, and mechanical inhalers have been proposed that utilize electrical energy to vaporize or heat volatile materials or attempt to provide the sensation of cigarette, cigar, or pipe smoking without burning tobacco to any significant extent. See, for example, the various alternative smoking articles, aerosol delivery devices, and heat sources described in the background art set forth in U.S. Pat. No. 7,726,320 (Robinson et al.), U.S. Patent Publication No. 2013 / 0255702 (Griffith Jr. et al.), U.S. Patent Publication No. 2014 / 0000638 (Sebastian et al.), U.S. Patent Publication No. 2014 / 0060554 (Collett et al.), U.S. Patent Publication No. 2014 / 0060555 (Chang et al.), U.S. Patent Publication No. 2014 / 0096781 (Sears et al.), U.S. Patent Publication No. 2014 / 0096782 (Ampolini et al.), and U.S. Patent Publication No. 2015 / 0059780 (Davis et al.), which are incorporated herein by reference in their entireties.
[0006] Certain types of these smoking articles, smokeless tobacco products, and electronic smoking articles contain tobacco extracts, which in some products may be refined so that the extract is composed primarily of nicotine. However, tobacco extracts containing high percentages of nicotine (including extracts containing at least about 90% by weight, at least about 95% by weight, and at least about 99% by weight nicotine) are typically in oil form. As such, nicotine extracts may be difficult to handle and incorporate into certain tobacco products.
[0007] It is desirable to provide such nicotine-based extracts in a form that is amenable to incorporation into tobacco products. It is further desirable to incorporate such extracts into enjoyable forms of tobacco products, and to provide processes for preparing such forms of nicotine-based extracts, as well as processes for preparing a variety of compositions and products incorporating such forms of nicotine-based extracts. [Prior art documents] [Patent documents]
[0008] [Patent Document 1] U.S. Pat. No. 5,101,839 [Patent Document 2] U.S. Pat. No. 5,159,944 [Patent Document 3] U.S. Patent No. 5,220,930 [Patent Document 4] U.S. Patent No. 6,779,530 [Patent Document 5] US Patent Application Publication No. 2005 / 0016556 [Patent Document 6] US Patent Application Publication No. 2005 / 0066986 [Patent Document 7] US Patent Application Publication No. 2005 / 0076929 [Patent Document 8] US Patent Application Publication No. 2006 / 0272655 [Patent Document 9] US Patent Application Publication No. 2007 / 0056600 [Patent Document 10] US Patent Application Publication No. 2007 / 0246055 [Patent Document 11] U.S. Pat. No. 1,376,586 [Patent Document 12] U.S. Pat. No. 3,696,917 [Patent Document 13] U.S. Pat. No. 4,513,756 [Patent Document 14] U.S. Pat. No. 4,528,993 [Patent Document 15] U.S. Pat. No. 4,624,269 [Patent Document 16] U.S. Pat. No. 4,991,599 [Patent Document 17] U.S. Pat. No. 4,987,907 [Patent Document 18] U.S. Patent No. 5,092,352 [Patent Document 19] U.S. Pat. No. 5,387,416 [Patent Document 20] U.S. Patent No. 6,668,839 [Patent Document 21] U.S. Patent No. 6,834,654 [Patent Document 22] U.S. Patent No. 6,953,040 [Patent Document 23] U.S. Patent No. 7,032,601 [Patent Document 24] U.S. Patent No. 7,694,686 [Patent Document 25] US Patent Publication No. 2004 / 0020503 [Patent Document 26] US Patent Publication No. 2005 / 0115580 [Patent Document 27] US Patent Publication No. 2006 / 0191548 [Patent Document 28] US Patent Publication No. 2007 / 0062549 [Patent Document 29] US Patent Publication No. 2007 / 0186941 [Patent Document 30] US Patent Publication No. 2007 / 0186942 [Patent Document 31] US Patent Publication No. 2008 / 0029110 [Patent Document 32] US Patent Publication No. 2008 / 0029116 [Patent Document 33] US Patent Publication No. 2008 / 0173317 [Patent Document 34] US Patent Publication No. 2008 / 0196730 [Patent Document 35] US Patent Publication No. 2008 / 0209586 [Patent Document 36] US Patent Publication No. 2008 / 0305216 [Patent Document 37] US Patent Publication No. 2009 / 0065013 [Patent Document 38] US Patent Publication No. 2009 / 0293889 [Patent Document 39] US Patent Publication No. 2010 / 0291245 [Patent Document 40] US Patent Publication No. 2011 / 0139164 [Patent Document 41] International Publication No. 2004 / 095959 [Patent Document 42] International Publication No. 2010 / 132444 [Patent Document 43] Patent No. 7,726,320 specification [Patent Document 44] US Patent Publication No. 2013 / 0255702 [Patent Document 45] US Patent Publication No. 2014 / 0000638 [Patent Document 46] US Patent Publication No. 2014 / 0060554 [Patent Document 47] US Patent Publication No. 2014 / 0060555 [Patent Document 48] US Patent Publication No. 2014 / 0096781 [Patent Document 49] US Patent Publication No. 2014 / 0096782 [Patent Document 50] US Patent Publication No. 2015 / 0059780 [Non-patent literature]
[0009] [Non-Patent Document 1] Johnson,Development of Cigarette Components to Meet Industry Needs,52ndT.SRC(September 1998) Summary of the Invention
[0010] The present invention provides various forms of nicotine that may be applicable to a wide range of products, including tobacco products. In particular, the present application describes nicotine salts, co-crystals, and salt co-crystals, as well as the preparation of such nicotine salts, co-crystals, and salt co-crystals. The incorporation of such nicotine salts, co-crystals, and / or salt co-crystals into various products, including tobacco products (e.g., smoking articles, smokeless tobacco products, and electronic smoking articles) and pharmaceutical products, is also described.
[0011] In a first aspect of the invention, there is provided a crystalline polymorphic form of a salt of nicotine and mucic acid, a salt of nicotine and 3,5-dihydroxybenzoic acid, a salt of nicotine and 2,3-dihydroxybenzoic acid, a crystalline polymorphic form of nicotine 1-hydroxy-2-naphthoate, which is characterized by an X-ray powder diffraction pattern having peaks at one or more (inclusive) of the following 2θ diffraction angles, namely 15.6, 16.1, 20.5, 22.5, and 27.1, a crystalline polymorphic form of nicotine 4-acetamidobenzoate, which is characterized by an X-ray powder diffraction pattern having peaks at one or more (inclusive) of the following 2θ diffraction angles, namely 16.839, 17.854, 20.134, and 23.265, and a crystalline polymorphic form of nicotine gentisate. A nicotine salt or crystalline polymorphic form is provided, the nicotine salt or crystalline polymorphic form being selected from the group consisting of a crystalline polymorphic form of nicotine salt or ...
[0012] In one embodiment, a salt formed from nicotine and mucic acid is provided, the salt being characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 14.289, 15,449, 19.66, and 20.412. In an additional embodiment, a salt formed from nicotine and 2,3-dihydroxybenzoic acid is provided, the salt being characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 12.4, 12.5, 15.2, 18.3, 19.7, 20.3, 20.9, 24.9, 25.2, 26.5, and 30.4.
[0013] In another embodiment, a salt formed from nicotine and 3,5-dihydroxybenzoic acid is provided which is an anhydrous form characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2θ diffraction angles: 12.7, 17.8, 19.7, 20.2, 21.3, 24.5, 24.9, 25.8, and 29.8. In a further embodiment, a salt formed from nicotine and 3,5-dihydroxybenzoic acid is provided which is an anhydrous form characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2θ diffraction angles: 10.7, 13.4, 15.0, 17.2, 17.3, 19.0, 21.4, 21.6, 22.2, 22.6, 22.9, 24.3, 25.1, 25.5, and 29.7. A given sample of salt formed from nicotine and 3,5-dihydroxybenzoic acid may contain entirely and / or substantially one single form, or may contain a mixture of varying amounts of two or more forms (including, but not limited to, the anhydrous and dihydrate forms referenced above).
[0014] The nicotine salts, co-crystals, and salt co-crystals described herein are generally applicable for use in a range of products, including, but not limited to, smoking articles, electronic smoking articles, smokeless tobacco products (e.g., lozenges and gums), pharmaceutical products, and the like. Accordingly, in another aspect of the invention, products are provided that incorporate one or more of the nicotine salts, co-crystals, and / or salt co-crystals described herein. In various embodiments, electronic smoking articles, smokeless tobacco products, and / or pharmaceutical products are provided that incorporate one or more of the salts, co-crystals, and / or salt co-crystal complexes disclosed herein.
[0015] For example, in one aspect, the disclosure provides an electronic smoking article comprising an inhalable substance medium within a cartridge body and a heating member positioned to provide heat to at least a portion of the inhalable substance medium, wherein the inhalable substance medium comprises a nicotine salt or crystalline polymorphic form disclosed herein (e.g., one or more salts or crystalline polymorphic forms selected from the group consisting of a salt of nicotine and mucic acid, a salt of nicotine and 3,5-dihydroxybenzoic acid, a salt of nicotine and 2,3-dihydroxybenzoic acid, a crystalline polymorphic form of nicotine 1-hydroxy-2-naphthoate), the form having peaks at one or more (including all) of the following 2θ diffraction angles: 15.6, 16.1, 20.5, 22.5, and 27.1. a crystalline polymorphic form of nicotine 4-acetamidobenzoate, which is characterized by an X-ray powder diffraction pattern having peaks at one or more (inclusive) of the following 2-theta diffraction angles: 16.839, 17.854, 20.134, and 23.265; and a crystalline polymorphic form of nicotine gentisate, which is characterized by an X-ray powder diffraction pattern having peaks at one or more (inclusive) of the following 2-theta diffraction angles: 13.000, 19.017, 20.194, and 21.000.
[0016] The inhalable substance medium may further include, for example, one or more of glycerin, water, and flavoring materials. The amount of nicotine salt or polymorphic form incorporated may, in some embodiments, be an amount sufficient to provide about 0.01 mg to about 0.5 mg, about 0.05 mg to about 0.3 mg, or about 0.1 mg to about 0.2 mg of nicotine per puff of the article.
[0017] In another aspect, the disclosure provides a nicotine salt or crystalline polymorphic form as described herein (e.g., one or more salts or crystalline polymorphic forms selected from the group consisting of a salt of nicotine and mucic acid, a salt of nicotine and 3,5-dihydroxybenzoic acid, a salt of nicotine and 2,3-dihydroxybenzoic acid, a crystalline polymorphic form of nicotine 1-hydroxy-2-naphthoate, wherein the form is characterized by an X-ray powder diffraction pattern having peaks at one or more (inclusive) of the following 2θ diffraction angles: 15.6, 16.1, 20.5, 22.5, and 27.1, a crystalline polymorphic form of nicotine 4-acetamidobenzoate, and a crystalline polymorphic form of nicotine gentisate, wherein the form is characterized by an X-ray powder diffraction pattern having peaks at one or more (inclusive) of the following 2-theta diffraction angles: 16.839, 17.854, 20.134, and 23.265; and a crystalline polymorphic form of nicotine gentisate, wherein the form is characterized by an X-ray powder diffraction pattern having peaks at one or more (inclusive) of the following 2-theta diffraction angles: 13.000, 19.017, 20.194, and 21.000. Exemplary smokeless tobacco products include, but are not limited to, loose moist snuff (e.g., snus); loose dry snuff; chewing tobacco; pelletized tobacco pieces; extruded or formed tobacco strips, pieces, rods, cylinders, or sticks; finely divided powders; finely divided or pulverized agglomerates of powdered pieces and ingredients; flake-like pieces; molded tobacco pieces; gums; rolls of tape-like film; water-soluble or water-dispersible films or strips; meltable compositions; lozenges; drops; and capsule-like materials having an outer shell and an interior region.
[0018] In a further aspect, the present disclosure provides a nicotine salt or crystalline polymorphic form described herein (e.g., a salt of nicotine and mucic acid, a salt of nicotine and 3,5-dihydroxybenzoic acid, a salt of nicotine and 2,3-dihydroxybenzoic acid, a salt of nicotine and 1-hydroxy-2-naphthoic acid, a crystalline polymorphic form of nicotine 4-acetamidobenzoate, wherein the form has a diffraction angle within any of the following 2θ diffraction angles: 16.839, 17.854, 20.134, and 23.265. and a crystalline polymorphic form of nicotine gentisate characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2θ diffraction angles: 13.000, 19.017, 20.194, and 21.000. Such products may be in a form selected from the group consisting of, for example, pills, tablets, lozenges, capsules, caplets, pouches, gums, inhalants, solutions, and creams. One exemplary lozenge formulation comprises one or more of the nicotine salts or crystalline polymorphic forms disclosed herein and at least about 50% by weight of isomalt.
[0019] Additionally, in still further aspects, the present disclosure provides methods for preparing certain nicotine salts and crystalline polymorphic forms. For example, the present disclosure provides methods for preparing nicotine mucate, including combining mucic acid and nicotine to form a solid, and isolating the solid. The present disclosure provides methods for preparing nicotine 3,5-dihydroxybenzoate, including combining 3,5-dihydroxybenzoic acid and nicotine to form a solid, and isolating the solid. In some embodiments, the resulting salt may include an anhydrous form. A hydrated form (e.g., a dihydrate form) may be prepared by exposing the anhydrous form to humidity as disclosed herein in certain embodiments. The present disclosure provides methods for preparing nicotine 2,3-dihydroxybenzoate, including combining 2,3-dihydroxybenzoic acid and nicotine to form a solid, and isolating the solid.
[0020] The present disclosure also provides a method for preparing a crystalline polymorphic form of nicotine 1-hydroxy-2-naphthoate, comprising combining 1-hydroxy-2-naphthoic acid and nicotine to form a solid, and isolating the solid. The present disclosure further provides a method for preparing a crystalline polymorphic form of nicotine 4-acetamidobenzoate, comprising combining equimolar amounts of 4-acetamidobenzoic acid and nicotine in a solvent (e.g., tetrahydrofuran) to form a solid, and isolating the solid. The present disclosure also provides a method for preparing a crystalline polymorphic form of nicotine gentisate, comprising combining equimolar amounts of gentisic acid and nicotine in a solvent (e.g., tetrahydrofuran) to form a solid, and isolating the solid.
[0021] The present invention includes, but is not limited to, the following embodiments.
[0022] Embodiment 1: A salt of nicotine and mucic acid, a salt of nicotine and 3,5-dihydroxybenzoic acid, a salt of nicotine and 2,3-dihydroxybenzoic acid, a crystalline polymorphic form of nicotine 1-hydroxy-2-naphthoate, the form being characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2θ diffraction angles: 15.6, 16.1, 20.5, 22.5, and 27.1, a crystalline polymorphic form of nicotine 4-acetamidobenzoate, the form being characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2θ diffraction angles: 15.6, 16.1, 20.5, 22.5, and 27.1, , i.e., 16.839, 17.854, 20.134, and 23.265, and a crystalline polymorphic form of nicotine gentisate, wherein the form is characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2θ diffraction angles: 13.000, 19.017, 20.194, and 21.000.
[0023] Embodiment 2: The nicotine salt or crystalline polymorphic form of any preceding or subsequent embodiment, comprising a salt of nicotine and mucic acid, wherein the form is characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 14.289, 15,449, 19.66, and 20.412.
[0024] Embodiment 3: The nicotine salt or crystalline polymorphic form of any preceding or subsequent embodiment, wherein at least about 50% of the salt or crystalline polymorphic form is in crystalline form.
[0025] Embodiment 4: The nicotine salt or crystalline polymorphic form of any of the preceding or subsequent embodiments, comprising a salt of nicotine and 3,5-dihydroxybenzoic acid, wherein the form is an anhydrous form characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 12.7, 17.8, 19.7, 20.2, 21.3, 24.5, 24.9, 25.8, and 29.8.
[0026] Embodiment 5: The nicotine salt or crystalline polymorphic form of any of the preceding or subsequent embodiments, comprising a salt of nicotine and 3,5-dihydroxybenzoic acid, wherein the form is a hydrated form characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 10.7, 13.4, 15.0, 17.2, 17.3, 19.0, 21.4, 21.6, 22.2, 22.6, 22.9, 24.3, 25.1, 25.5, and 29.7.
[0027] Embodiment 6: The nicotine salt or crystalline polymorphic form of any preceding or subsequent embodiment, comprising a salt of nicotine and 2,3-dihydroxybenzoic acid, wherein the form is characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 12.4, 12.5, 15.2, 18.3, 19.7, 20.3, 20.9, 24.9, 25.2, 26.5, and 30.4.
[0028] Embodiment 7: An electronic smoking article comprising an inhalable substance medium contained within a cartridge body and a heating member positioned to provide heat to at least a portion of the inhalable substance medium, wherein the inhalable substance medium comprises one or more of the nicotine salts or crystalline polymorphic forms of any of the preceding or subsequent embodiments.
[0029] Embodiment 8: The electronic smoking article of any preceding or subsequent embodiment, wherein the inhalable substance medium further comprises one or more of glycerin, water, and flavorants.
[0030] Embodiment 9: The electronic smoking article of any preceding or subsequent embodiment, wherein the amount of nicotine salt or crystalline polymorphic form is sufficient to provide an amount of nicotine per puff of the article in an amount of about 0.01 mg to about 0.5 mg.
[0031] Embodiment 10: The electronic smoking article of any preceding or subsequent embodiment, wherein the amount of nicotine salt or crystalline polymorphic form is sufficient to provide an amount of nicotine per puff of the article in an amount of about 0.05 mg to about 0.3 mg.
[0032] Embodiment 11: The electronic smoking article of any preceding or subsequent embodiment, wherein the amount of nicotine salt or crystalline polymorphic form is sufficient to provide an amount of nicotine per puff of the article in an amount of about 0.1 mg to about 0.2 mg.
[0033] Embodiment 12: A smokeless tobacco product comprising one or more of the nicotine salts or crystalline polymorphic forms of any of the preceding or subsequent embodiments.
[0034] Embodiment 13: A smokeless tobacco product according to any preceding or subsequent embodiment, selected from the group consisting of loose moist snuff (e.g., snus); loose dry snuff; chewing tobacco; pelletized tobacco pieces; extruded or formed tobacco strips, pieces, rods, cylinders, or sticks; finely divided powders; finely divided or pulverized agglomerates of powdered pieces and ingredients; flake-like pieces; molded tobacco pieces; gums; rolls of tape-like films; water-soluble or water-dispersible films or strips; meltable compositions; lozenges; drops; and capsule-like materials having an outer shell and an interior region.
[0035] Embodiment 14: A pharmaceutical product comprising one or more of the nicotine salts or crystalline polymorphic forms of any of the preceding or subsequent embodiments.
[0036] Embodiment 15: The pharmaceutical product of any preceding or subsequent embodiment, in a form selected from the group consisting of a pill, tablet, lozenge, capsule, caplet, pouch, gum, inhalant, solution, and cream.
[0037] Embodiment 16: A lozenge comprising one or more nicotine salts or crystalline polymorphic forms of any of the preceding or subsequent embodiments, and at least about 50% by weight of isomalt.
[0038] These and other features, aspects, and advantages of the present disclosure will become apparent from a reading of the following detailed description in conjunction with the accompanying drawings, which are briefly described below. The present invention includes any combination of two, three, four, or more of the above-described embodiments, as well as any combination of two, three, four, or more features or elements set forth in this disclosure, whether or not such features or elements are expressly combined in the description of a particular embodiment herein. This disclosure is intended to be read in its entirety such that any separable features or elements of the disclosed invention should be viewed as intended to be combinable in any of its various aspects and embodiments, unless the context clearly indicates otherwise.
[0039] To provide an understanding of embodiments of the present invention, reference is made to the accompanying drawings, which are not necessarily to scale, and in which reference numerals refer to components of exemplary embodiments of the present invention. The drawings are merely illustrative and should not be considered as limiting the present invention. [Brief description of the drawings]
[0040] [Figure 1] 1 is an X-ray powder diffraction pattern of nicotine mucate. [Diagram 2] 1H NMR spectrum of nicotine mucate. [Diagram 3] FIG. 1 is an X-ray powder diffraction pattern of crystalline nicotine 4-acetamidobenzoate, showing the experimental pattern and the pattern calculated from the single crystal X-ray structure. [Figure 4A] FIG. 4A is a representation of the crystal structure obtained for two independent molecules of nicotine 4-acetamidobenzoate. [Figure 4B] FIG. 4B is a representation of the crystal structure obtained for two independent molecules of nicotine 4-acetamidobenzoate. [Figure 4C]FIG. 4C is a diagram of the crystal packing of nicotine 4-acetamidobenzoate. [Diagram 5] FIG. 1 is an X-ray powder diffraction pattern of crystalline nicotine gentisate, showing the experimental pattern and the pattern calculated from the single crystal X-ray structure. [Figure 6A] FIG. 6A is a representation of the crystal structure obtained for nicotine gentisate. [Figure 6B] FIG. 6B is a diagram of the crystal packing of nicotine gentisate. [Figure 7] 1 is an X-ray powder diffraction pattern of nicotine 3-hydroxybenzoate. [Figure 8] 1 is an X-ray powder diffraction pattern of nicotine malate. [Figure 9] FIG. 1 is an X-ray powder diffraction pattern of anhydrous nicotine 3,5-dihydroxybenzoate, showing the experimental pattern and the pattern calculated from the single crystal X-ray structure. [Figure 10] 1H NMR spectrum of anhydrous nicotine 3,5-dihydroxybenzoate. [Figure 11] 1 is an X-ray powder diffraction pattern of nicotine 3,5-dihydroxybenzoate dihydrate. [Figure 12] 1H NMR spectrum of nicotine 3,5-dihydroxybenzoate dihydrate. [Figure 13] FIG. 2 is a diagram of the crystal structure obtained for anhydrous nicotine 3,5-dihydroxybenzoate. [Figure 14A] FIG. 14A is a plot showing hydrogen bonding in the asymmetric unit of anhydrous nicotine 3,5-dihydroxybenzoate. [Figure 14B] FIG. 14B is a diagram of the crystal packing of anhydrous nicotine 3,5-dihydroxybenzoate. [Figure 15] 1 is an X-ray powder diffraction pattern of nicotine 2,3-dihydroxybenzoate. [Figure 16] 1H NMR spectrum of nicotine 2,3-dihydroxybenzoate. [Figure 17]1 is an X-ray powder diffraction pattern of nicotine 1-hydroxy-2-naphthoate. [Figure 18] 1H NMR spectrum of nicotine 1-hydroxy-2-naphthoate. [Figure 19] 1 is an exploded perspective view of a smoking article having the form of a cigarette, showing smokable material, wrapping material components, and a filter element of the cigarette. [Figure 20] 1 is a cross-sectional view of an embodiment of a smokeless tobacco product taken across the width of the product, showing an outer pouch filled with a smokeless tobacco composition of the present invention. [Figure 21] FIG. 1 is a cross-sectional view of an electronic smoking article, which may include various combinations of components useful in forming an electronic aerosol delivery device. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0041] The present invention will now be described more fully below. However, the present invention may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein, but rather these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. As used in this specification and claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. References to "dry weight percent" or "dry weight basis" refer to weight based on dry ingredients (i.e., all ingredients excluding water).
[0042] The present invention relates to nicotine salts, co-crystals, and salt co-crystals, and methods for their preparation. It also relates to products (including tobacco products and pharmaceutical products) that include one or more nicotine salts, co-crystals, and / or salt co-crystals. In certain embodiments, nicotine provided in one or more such forms may be advantageously isolated in a physical form that is an improvement over pure nicotine, which is a hygroscopic oily liquid. For example, in certain embodiments, the nicotine salts, co-crystals, and / or salt co-crystals described herein may be in a form that is easier to handle than pure nicotine (e.g., solid or semi-solid form), may be provided in a form of higher purity than pure nicotine, and / or may exhibit superior thermodynamic, physical, and / or chemical stability (e.g., higher antioxidant properties, reduced risk of hydrate formation, and / or longer shelf life) than pure nicotine. In some embodiments, the nicotine salts, co-crystals, and / or salt co-crystals may provide increased stability in the presence of relevant excipients in the product in which the salts, co-crystals, and / or salt co-crystals are incorporated, as compared to pure nicotine. In some embodiments, the nicotine salts, co-crystals, and salt co-crystals can exhibit a significant degree of water solubility, making them applicable for incorporation within a wide range of compositions and products.
[0043] Nicotine itself can be isolated and / or processed so that it can be in one of two enantiomeric forms or can be provided in racemic form. Nicotine is the naturally occurring levorotatory (L)-nicotine form (also known as (-)-nicotine or S-nicotine). In the salts, cocrystals, and salt cocrystals provided herein, nicotine is generally in the form of (L)-nicotine, but the present disclosure is not intended to exclude the preparation and application of dextrorotatory ((D)-nicotine) salts, cocrystals, and salt cocrystals, or the racemic form of nicotine in the disclosed salts, cocrystals, and salt cocrystals. Thus, nicotine salts, cocrystals, and salt cocrystals can be in enantiomerically pure form (i.e., (L)- or (D)-form) or the racemic form described herein.
[0044] A "nicotine salt" is a form of nicotine characterized by the interaction between nicotine in ionic form and a coformer (e.g., an acid) in ionic form via the transfer of one or more protons from a coformer donor to a nicotine acceptor. The structure of nicotine is such that it contains two nitrogen atoms that can accept protons from the coformer, and therefore, it can exist in a given sample in unprotonated, monoprotonated, and / or diprotonated forms.
[0045] Certain nicotine salts are currently known. For example, nicotine sulfate is sold as an insecticide, and nicotine bitartrate dihydrate (also known as nicotine hydrogen tartrate) is a commercially available water-soluble nicotine salt. Various other salts have been investigated, including nicotine acetate (which forms a viscous oil) as well as nicotine citrate and nicotine malate. See, for example, U.S. Pat. No. 2,033,909 (Cox et al.), and the types of materials and techniques described in Perfetti, Beitrage Tabakforschung Int., 12, 43-54 (1983). Additionally, certain nicotine salts are available from sources such as Pfaltz and Bauer, Inc. and K&K Laboratories, Division of ICN Biochemicals, Inc. Exemplary known nicotine salts include nicotine salts such as nicotine tartrate and nicotine bitartrate, nicotine chloride (e.g., nicotine hydrochloride and nicotine dihydrochloride), nicotine sulfate, nicotine perchlorate, nicotine ascorbate, nicotine fumarate, nicotine citrate, nicotine maleate, nicotine lactate, nicotine aspartate, nicotine salicylate, nicotine tosylate, nicotine succinate, nicotine pyruvate, and nicotine salt hydrates (e.g., nicotine zinc chloride monohydrate). Nicotine salts with levulinic acid are discussed in U.S. Patent Application Publication No. 2011 / 0268809 and International Application Publication No. PCT / US2011 / 033928 (both to Brinkley et al.), which are incorporated herein by reference. See, e.g., U.S. Patent Nos. 4,830,028 (Lawson et al.) and 5,031,646 (Lippiello et al.), and also Leonard, Ind. Eng. Chem. 48:1331-1341 (1956). However, certain previously disclosed nicotine salts of organic acids are generally not crystalline and may exhibit a range of stoichiometries, which may make them unsuitable for use in certain applications.
[0046] A "nicotine cocrystal" is a form of nicotine that includes nicotine and at least one other component (a "coformer"), both in neutral form. Cocrystals are typically characterized by a crystal structure and are generally held together by reversible non-covalent interactions. Cocrystals are typically formed with nicotine and at least one other component in a defined stoichiometric ratio. In some embodiments, cocrystals may include hydrates, solvates, and clathrates. Cocrystals may include nicotine in combination with organic and / or inorganic components. Cocrystals may generally be distinguished from salts by the absence of proton transfer between the components in the cocrystal (i.e., nicotine and one or more coformers). In accordance with the U.S. Food and Drug Administration's Guidance for Industry (April 2013), a cocrystal is defined as a solid, a crystalline material composed of two or more molecules in the same crystal lattice, where the components are in a neutral state and interact through non-ionic interactions. See U.S. Department of Health and Human Services, Food and Drug Administration, Guidance for Industry, Regulatory Classification of Pharmaceutical Co-Crystals (April 2013), incorporated herein by reference.
[0047] A "nicotine salt co-crystal" is a type of hybrid structure that has both salt and co-crystal characteristics. Typically, a nicotine molecule in a salt co-crystal is associated with at least two coformers (which can be the same or different), one coformer being in an ionic form (e.g., an acid) and transferring a proton to the nicotine molecule, and the second coformer not transferring a proton to the nicotine molecule.
[0048] The salts, co-crystals, and salt co-crystals described herein can vary. For example, in certain embodiments where two components are present (i.e., nicotine and one co-former), the stoichiometry of nicotine:co-former can range from about 5:1 to about 1:5 nicotine:co-former in certain embodiments. When multiple co-formers are used to form nicotine salts, co-crystals, or salt co-crystals, the ratios of the co-formers relative to nicotine and each other can all vary. In preferred embodiments, a given sample of salts, co-crystals, and salt co-crystals provided according to the present disclosure exhibits substantially one single stoichiometry.
[0049] The salts, cocrystals, and salt cocrystals described herein, in some embodiments, exist in various polymorphic and pseudopolymorphic forms. Polymorphism is the ability of a crystalline material to exist in multiple forms or crystal structures. Polymorphism can result, for example, from the existence of different crystal packing structures (packing polymorphism) or from the existence of different coformers of the same molecule (conformational polymorphism). Pseudopolymorphism is the result of hydration or solvation of a material and is also referred to as solvation polymorphism.
[0050] The salts, cocrystals, and salt cocrystals of the present disclosure can incorporate nicotine derived from some forms of Nicotiana species plants (e.g., some forms of tobacco). The nicotine can be in the form of, for example, highly purified tobacco extracts. Various methods are known for the isolation and purification of nicotine from tobacco (extraction from tobacco with water, extraction from tobacco with organic solvents, steam distillation from tobacco, or pyrolytic decomposition of tobacco and distillation of nicotine therefrom). For exemplary extraction methods, see, for example, U.S. Pat. Nos. 2,822,306 and 4,153,063 (Roselius et al.), and U.S. Patent Application Publication No. 2008 / 0302377 (Kauryzbaev et al.), which are incorporated herein by reference.
[0051] The selection of plants from the Nicotiana species from which such extracts and other tobacco materials that may be complexed with the salts, co-crystals, and / or salt co-crystals described herein are derived may vary, particularly the type of tobacco(s). Tobaccos that may be used include iron-cured or Virginia (e.g., K326), Burley, sun-cured (e.g., Indian Carnoor and Oriental tobaccos, including Katerini, Prelip, Komotini, Xanthi, and Yambol tobaccos), Maryland, dark, dark burnt, dark air-cured (e.g., Passanda, Cubano, Jatin, and Bezuki tobaccos), light air-cured (e.g., North Wisconsin and Galpao tobaccos), Indian air-cured, Red Russian, and Rustic tobaccos, as well as various other rare or specialty tobaccos. Descriptions of various types of tobacco, cultivation, and harvesting are provided in Tobacco Production, Chemistry and Technology, Davis et al. (Eds.) (1999), incorporated herein by reference. Nicotiana species may be derived using genetic modification or cross-breeding techniques (e.g., tobacco plants may be genetically engineered or cross-bred to increase or decrease the production of certain components, characteristics, or attributes, or to make other changes). Additional information regarding the types of Nicotiana species suitable for use in the present invention may be found in U.S. Patent Application Publication No. 2012 / 0192880 (Dube et al.), which is incorporated herein by reference. Tobacco plants may be grown in greenhouses, growth chambers, or outdoor fields, or may be grown hydroponically.
[0052] The part(s) of the plant of Nicotiana species used according to the present invention may vary. For example, substantially the entire plant (e.g., the whole plant) is harvested and used as such. Alternatively, various parts or pieces of the plant may be harvested or separated for further use after harvesting. For example, leaves, stems, petioles, roots, lamina, flowers, seeds, as well as various parts and combinations thereof may be isolated for further use or processing. Thus, the plant material of the present invention may include the entire plant of Nicotiana species or any part of the plant. See, for example, the parts of the tobacco plant described in U.S. Patent Application Publication Nos. 2011 / 0174323 (Coleman, III et al.) and 2012 / 0192880 (Dube et al.), which are incorporated herein by reference.
[0053] Nicotiana species plants can be used in either precocious or mature forms, as described in U.S. Patent Publication No. 2012 / 0192880 (Dube et al.), which is incorporated herein by reference, and can be used in either fresh or dried form. The tobacco material can be subjected to various treatment processes, such as refrigeration, freezing, drying (e.g., freeze-drying or spray-drying), irradiation, yellowing, heating, cooking (e.g., roasting, frying, or boiling), fermentation, bleaching, or otherwise stored or processed for later use. Exemplary processing techniques are described, for example, in U.S. Patent Publication Nos. 2009 / 0025739 (Brinkley et al.) and 2011 / 0174323 (Coleman, III et al.), which are incorporated herein by reference. At least a portion of a plant of the Nicotiana species can be treated with enzymes and / or probiotics before or after harvest, as discussed in U.S. Patent Application Publication Nos. 2013 / 0269719 (Marshall et al.) and 2014 / 0020694 (Moldoveanu), which are incorporated herein by reference.
[0054] The harvested part or parts of the plant of Nicotiana species can be physically processed. The part or parts of the plant can be separated into individual parts or pieces (e.g., roots can be removed from the petioles, stems can be removed from the petioles, leaves can be removed from the petioles and / or stems, and petals can be removed from the rest of the flower). The harvested part or parts of the plant can be further subdivided into parts or pieces (e.g., broken, cut, comminuted, crushed, milled, or ground into pieces or parts that can be characterized as filler-type pieces, granules, particles, or fine powders). The harvested part or parts of the plant can be subjected to an external force or pressure (e.g., by being pressed or rolled). When such processing conditions are performed, the harvested part or parts of the plant may have a moisture content that approximates its natural moisture content (e.g., its moisture content immediately after harvest), a moisture content achieved by the addition of moisture to the harvested part or parts of the plant, or a moisture content resulting from drying the harvested part or parts of the plant. As such, the harvested part or parts of the plant may be used, such as an ingredient in a tobacco product, or may be further processed.
[0055] To provide a nicotine extract, a plant of the Nicotiana species or a part thereof is typically subjected to one or more types of processing conditions. A typical separation process may include one or more process steps (e.g., solvent extraction using a polar solvent, an organic solvent, and / or a supercritical fluid), chromatography, distillation, filtration, recrystallization, and / or solvent-solvent partitioning. Exemplary extraction and separation solvents or carriers include water, alcohols (e.g., methanol or ethanol), hydrocarbons (e.g., heptane and hexane), hydrogenated hydrocarbons (e.g., monofluorotrichloromethane (Freon 11), dichlorotrifluoroethane (Freon 123), etc.), diethyl ether, methylene chloride, and supercritical carbon dioxide. See, for example, the descriptions of isolated tobacco components and techniques for isolation in U.S. Pat. No. 4,967,771 (Fagg et al.), U.S. Patent Application Publication Nos. 2011 / 0174323 (Coleman, III et al.), 2011 / 0259353 (Coleman, III et al.), 2012 / 0192880 (Dube et al.), 2012 / 0192882 (Dube et al.), and 2012 / 0211016 (Byrd, Jr. et al.), which are incorporated herein by reference.
[0056] The nicotine incorporated in the salts, co-crystals, and salt co-crystals of the present disclosure is generally derived from some form of the Nicotiana species of plant as outlined above, although the source of the nicotine is not so limited. For example, in some embodiments, the nicotine may be provided synthetically. In some embodiments, the nicotine may be obtained from another source (e.g., another type of plant).
[0057] Nicotine is typically isolated (e.g., as described above) in undiluted (liquid) form. In accordance with the present invention, nicotine is modified so that it is provided in other forms by incorporating nicotine as a component of a salt, co-crystal, or salt co-crystal, e.g., in the form of an oil, solid, semi-solid, etc. In some embodiments, certain salts, co-crystals, and salt co-crystals are desirably provided in a solid form, e.g., a solid crystalline form. Advantageously (but not necessarily), the coformer (including acids) that is complexed with nicotine to form such nicotine salts, co-crystals, or salt co-crystals is "GRAS" (Generally Recognized As Safe) according to the U.S. Food and Drug Administration. Additionally, it is beneficial (also not required) that the nicotine salts, co-crystals, and / or salt co-crystals produced thereby are also GRAS.
[0058] In one embodiment, nicotine mucate (also called nicotine galactarate) is provided. Nicotine mucate is formed from nicotine and mucic acid (also known as (2S,3R,4S,5R)-2,3,4,5-tetrahydroxyhexanedioic acid, hexacid, galactaric acid, meso-galactaric acid, saccharolactic acid, tetrahydroxyadipic acid, tetrahydroxyhexanedioic acid). In one aspect, nicotine mucate is provided with a nicotine:acid stoichiometry of about 2:1 to about 1:2. In certain embodiments, nicotine mucate is provided with a nicotine:acid stoichiometry of about 2:1 to about 1:1 (i.e., with no more than one equivalent of acid per nicotine).
[0059] It should be noted that in some embodiments, the extract form of nicotine mucate prepared according to the present disclosure may not be known. In one embodiment, nicotine mucate is prepared as described in Example 1, 1Analysis by H NMR showed that the solid consisted of 0.72 equivalents of acid. Without intending to be limiting, this determination may be consistent with, for example, a nicotine mucate cocrystal having a hemi-mucate structure with an additional mucate molecule associated therewith (by hydrogen bonding). However, it is possible that the nicotine mucate prepared and reported herein is in fact a hemi-mucate (i.e., consisting of 0.5 equivalents of acid).
[0060] In certain embodiments, nicotine mucate is provided in solid form and may be in crystalline and / or amorphous form. Exemplary X-ray powder diffraction (XRPD) patterns of samples containing crystalline and amorphous forms of nicotine mucate are provided in FIG. 1. Nicotine mucate may be described as exhibiting an XRPD pattern with peaks at one or more of the following 2θ diffraction angles: 14.289°, 15,449°, 19.66°, and 20.412°. Full characterization data, including a table of all relevant peaks in the X-ray diffraction pattern, is provided in Example 1. This material 1 The 1 H NMR spectrum is provided in FIG.
[0061] Advantageously, in certain embodiments, samples of nicotine mucate are provided that contain at least a certain percentage of the form described herein. For example, in some embodiments, samples of nicotine mucate are provided that contain at least about 70% by weight, at least about 75% by weight, at least about 80% by weight, at least about 85% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight, at least about 98% by weight, or at least about 99% by weight of the form described herein.
[0062] Consistent with a crystalline form, nicotine mucate may, in some embodiments, exhibit a relatively sharp melting point. For example, in certain embodiments, nicotine mucate may exhibit a distinct melting point beginning at about 120°C to about 125°C (e.g., about 123°C). Consistent with an amorphous form, nicotine mucate may, in certain embodiments, lack a distinct melting point. Amorphous nicotine mucate may exhibit a broad melting range. In certain embodiments, nicotine mucate may exhibit a melting range beginning at about 133°C. Samples that exist as a mixture of amorphous and crystalline nicotine mucate may exhibit both a relatively sharp melting point and a broad melting range. The ratio of crystalline to amorphous nicotine mucate may vary, and may be, for example, about 10:90 to about 90:10.
[0063] In certain embodiments, polarized light microscopy (PLM) of nicotine mucate shows irregular birefringent particles, typically less than about 10 μm. However, it is noted that these particles may exhibit different sizes and / or shapes, which may depend on the method of preparation and / or the ratio of amorphous to crystalline solids present in the analyzed sample.
[0064] In another aspect of the present disclosure, a specific crystalline form of nicotine 4-acetamidobenzoate has been isolated and characterized. Salts of acetamidobenzoic acid have been previously described. See, for example, Lasslo et al., J. Amer. Pharm. Assoc. (1912-1977) (1959), 48, 345-7, and Gialdi et al., Farmaco, Edizione Scientifica (1959), 14, 15-24, which are incorporated herein by reference. In accordance with certain aspects of the present invention, novel crystalline forms are provided and described according to certain parameters as described herein.
[0065] This novel crystalline form of nicotine 4-acetamidobenzoate may, in some embodiments, be characterized by an X-ray powder diffraction (XRPD) pattern, as shown in Figure 3. The agreement between the experimental pattern from the bulk sample and the pattern calculated from the single crystal X-ray structure is good. The XRPD pattern is obtained as described in the experimental section of this disclosure.
[0066] Full characterization data for nicotine 4-acetamidobenzoate, including a table of all relevant peaks in the X-ray diffraction pattern of nicotine 4-acetamidobenzoate, is provided in Example 2. Nicotine 4-acetamidobenzoate may be described as exhibiting an XRPD pattern having peaks at one or more of the following 2θ diffraction angles: 16.839°, 17.854°, 20.134°, and 23.265°. Consistent with a crystalline form, this nicotine 4-acetamidobenzoate form exhibits a discrete melting point with an onset at about 130° C. to about 135° C. (e.g., about 134° C.).
[0067] Advantageously, in certain embodiments, samples of nicotine 4-acetamidobenzoate are provided that contain at least a certain percentage of the crystalline polymorphic form described herein. For example, in some embodiments, samples of nicotine 4-acetamidobenzoate are provided that contain at least about 70% by weight, at least about 75% by weight, at least about 80% by weight, at least about 85% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight, at least about 98% by weight, or at least about 99% by weight of the polymorphic form described herein.
[0068] A single crystal X-ray diffraction (SCXRD) structure was obtained for this crystalline form of nicotine 4-acetamidobenzoate, as shown in Figures 4A and 4B (showing two independent molecules of nicotine 4-acetamidobenzoate). The SCXRD structure was obtained as described in the experimental section of this disclosure. Ellipticity of anisotropic atomic displacements for non-hydrogen atoms is shown at the 50% probability level. Hydrogen bonds are shown as dashed lines. Hydrogen atoms are shown with an arbitrary small radius. In certain embodiments, at least a given percentage of the crystalline nicotine 4-acetamidobenzoate provided as described herein is in a single crystalline form. For example, in some embodiments, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% of the crystalline 4-acetamidobenzoate is in a single crystalline form.
[0069] It is evident from the X-ray structure that a proton has been transferred, confirming the form as a salt. The X-ray structure further indicates that nicotine is the S enantiomer. The SCXRD structure of nicotine 4-acetamidobenzoate further shows a hydrogen-bonded head-to-tail arrangement of acid molecules (the acid carbonyl of one molecule hydrogen bonds to the NH functionality in the second molecule) with nicotine molecules attached at regular intervals. This form of nicotine 4-acetamidobenzoate can be described as having a monoclinic crystal system.
[0070] In certain embodiments, the disclosed nicotine 4-acetamidobenzoate exhibits physical properties that make it suitable for incorporation into a variety of products. For example, in some embodiments, the disclosed form is not significantly hygroscopic, with the majority of its observed water absorption being within the 80-90% relative humidity range. Thus, storage of this form is possible, provided that the relative humidity level of the environment in which it is stored is appropriately controlled.
[0071] In another aspect of the present disclosure, a particular crystalline form of nicotine 2,5-dihydroxybenzoate (i.e., nicotine gentisate) has been isolated and characterized. Salts of nicotine gentisate have been previously described. See, e.g., Perfetti, Beitraege zur Tabakforschung International (1983), 12(2), 43-54; Dezelic et al., Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy (1967), 23(4), 1149-53; Nikolin et al., Arhiv za Higijenu Rada i Toksikologiju (1966), 17(3), 303-8; Dezelic et al., Glasnik Hemicara Technol. Bosne Hercegovine et al. (1965), 13-14, 27-36; and Dezelic et al., Glasnik Drustva Hem. Technol. NR Bosne Hercegovine (1961), 10, 55-62, which are incorporated herein by reference. In accordance with certain aspects of the present invention, novel crystalline forms of nicotine gentisate are provided and are described according to certain parameters as described herein.
[0072] This novel crystalline form of nicotine gentisate may, in some embodiments, be characterized by an X-ray powder diffraction (XRPD) pattern, as shown in FIG. 5. The agreement between the experimental pattern from the bulk sample and the pattern calculated from the single crystal X-ray structure is good. The XRPD pattern is obtained as described in the experimental section of this disclosure. Full characterization data, including a table of all relevant peaks in the X-ray diffraction pattern, is provided in Example 3. Nicotine mucate may be described as exhibiting an XRPD pattern with peaks at one or more of the following 2θ diffraction angles: 13.000°, 19.017°, 20.194°, and 21.000°. Consistent with a crystalline form, this nicotine 2,5-hydroxybenzoate form exhibits a distinct melting point with an onset at about 145° C. to about 150° C. (e.g., about 149° C.).
[0073] Advantageously, in certain embodiments, a sample of nicotine gentisate is provided, in which at least a certain percentage comprises the crystalline polymorphic form described herein.For example, in some embodiments, a sample of nicotine gentisate is provided, in which at least about 70% by weight, at least about 75% by weight, at least about 80% by weight, at least about 85% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight, at least about 98% by weight, or at least about 99% by weight comprises the polymorphic form described herein.
[0074] A single crystal X-ray diffraction (SCXRD) structure was obtained for this crystalline form of nicotine gentisate, as shown in FIG. 6A. The SCXRD structure was obtained as described in the experimental section of this disclosure. The ellipticity of the anisotropic atomic displacements for non-hydrogen atoms is shown at the 50% probability level. Hydrogen bonds are shown as dashed lines. Hydrogen atoms are shown with an arbitrary small radius. In certain embodiments, at least a given percentage of the crystalline nicotine gentisate provided as described herein is in a single crystalline form. For example, in some embodiments, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% of the crystalline gentisate is in a single crystalline form. The crystal packing of the obtained nicotine gentisate is provided in FIG. 6B.
[0075] The transfer of protons is evident from the X-ray structure of nicotine gentisate, confirming that the form is a salt. The SCXRD structure of nicotine gentisate further shows a hydrogen-bonded head-to-tail arrangement of acid molecules (one molecule hydrogen-bonded to the second molecule) with nicotine molecules bonded at regular intervals. This form of nicotine gentisate can be described as having a monoclinic crystal system.
[0076] In certain embodiments, the disclosed nicotine gentisate exhibits physical properties that make it suitable for incorporation into various products.In fact, the disclosed forms of nicotine gentisate exhibit lower hygroscopicity and better thermal stability than commercially available ditartrate dihydrate, as evidenced, for example, by the thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) studies described herein.
[0077] In further embodiments, nicotine 3-hydroxybenzoate and nicotine malate are provided. XRPD patterns for these salts are provided in Figures 7 and 8, respectively. Additional data for these salts are provided in Examples 4 and 5.
[0078] In another aspect of the present invention, nicotine 3,5-dihydroxybenzoate is provided. Nicotine 3,5-dihydroxybenzoate is formed from nicotine and 3,5-dihydroxybenzoic acid. In one aspect, nicotine 3,5-dihydroxybenzoate is provided having a nicotine:acid stoichiometry of about 1:1. In certain embodiments, nicotine 3,5-dihydroxybenzoate is provided in a solid form, which may be in a crystalline form and / or an amorphous form.
[0079] In some embodiments, nicotine 3,5-dihydroxybenzoate may exist in anhydrous form and / or one or more hydrated (e.g., dihydrate) forms. Thus, nicotine 3,5-dihydroxybenzoate may undergo form changes when exposed to different humidity levels. An exemplary powder diffraction (XRPD) pattern of anhydrous nicotine 3,5-dihydroxybenzoate is provided in FIG. 9. The agreement between the experimental pattern from the bulk sample and the pattern calculated from the single crystal X-ray structure is good. Anhydrous nicotine 3,5-dihydroxybenzoate may be described as exhibiting an XRPD pattern with peaks at one or more of the following 2θ diffraction angles: 12.7°, 17.8°, 19.7°, 20.2°, 21.3°, 24.5°, 24.9°, 25.8°, and 29.8°. Full characterization data, including a table of all relevant peaks in the X-ray diffraction pattern, is provided in Example 6. The anhydrous form of this material 1 The 1 H NMR spectrum is provided in FIG.
[0080] The XRPD pattern of nicotine 3,5-dihydroxybenzoate dihydrate (prepared by exposure of the anhydrous form to humidity) is provided in Figure 11. Nicotine 3,5-dihydroxybenzoate dihydrate can be described as exhibiting an XRPD pattern with peaks at one or more of the following 2θ diffraction angles: 10.7°, 13.4°, 15.0°, 17.2°, 17.3°, 19.0°, 21.4°, 21.6°, 22.2°, 22.6°, 22.9°, 24.3°, 25.1°, 25.5°, and 29.7°. Full characterization data, including a table of all relevant peaks in the X-ray diffraction pattern, is provided in Example 6. The dihydrate form of this material 1 The H NMR spectrum is provided in Figure 12. Note that a VH-XRPD experiment confirmed the presence of this dihydrate form (exhibiting the same XRPD diffractogram as material resulting from storage of the anhydrous form at 25°C / 96% relative humidity). In some embodiments, the dihydrate form may be converted back to the anhydrous form mentioned above upon heating.
[0081] A single crystal X-ray diffraction (SCXRD) structure was obtained for the crystalline form of anhydrous nicotine 3,5-hydroxybenzoate, as shown in FIG. 13. The SCXRD structure was obtained as described in the experimental section of this disclosure. Ellipticity of anisotropic atomic displacements for non-hydrogen atoms is shown at the 50% probability level. Hydrogen bonds are shown as dashed lines. Hydrogen atoms are shown with an arbitrary small radius. In certain embodiments, at least a given percentage of the crystalline nicotine 3,5-dihydroxybenzoate provided as described herein is in a single crystalline form. For example, in some embodiments, at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, or at least about 90% by weight of the crystalline 3,5-dihydroxybenzoate is in a single crystalline form. A plot showing the hydrogen bonding in the asymmetric unit of anhydrous nicotine 3,5-dihydroxybenzoate is presented in FIG. 14A, and the resulting crystal packing of anhydrous nicotine 3,5-dihydroxybenzoate is provided in FIG. 14B.
[0082] Consistent with the crystalline form, nicotine 3,5-dihydroxybenzoate may, in some embodiments, exhibit a relatively sharp melting point. For example, in certain embodiments, nicotine 3,5-dihydroxybenzoate may exhibit a distinct melting point beginning at about 138° C. for the anhydrous form. The dihydrate form is believed to melt at about 137° C. (with an endotherm at 50-100° C.), and while not intending to be limited by theory, it is believed that the dihydrate is converted to the anhydrous form over a temperature range of 50-100° C., and then the converted anhydrous form melts at about 137° C. In certain embodiments, polarized light microscopy of nicotine 3,5-dihydroxybenzoate reveals irregular particles, typically less than about 10 μm in size. However, it should be noted that these particles may exhibit different sizes and / or shapes, which may depend on the method of preparation and / or the ratio of amorphous to crystalline solids present in the analyzed sample.
[0083] In another aspect, nicotine 2,3-dihydroxybenzoate is provided. Nicotine 2,3-dihydroxybenzoate is formed from nicotine and 2,3-dihydroxybenzoic acid. In one aspect, nicotine 2,3-dihydroxybenzoate is provided having a nicotine:acid stoichiometry of about 1:1. In certain embodiments, nicotine 2,3-dihydroxybenzoate is provided in a solid form, which may be in a crystalline form and / or an amorphous form.
[0084] In certain embodiments, nicotine 2,3-dihydroxybenzoate is provided in a solid form, which may be crystalline and / or amorphous. An exemplary X-ray powder diffraction (XRPD) pattern of a sample containing nicotine 2,3-dihydroxybenzoate is provided in FIG. 15. Nicotine 2,3-dihydroxybenzoate may be described as exhibiting an XRPD pattern having peaks at one or more of the following 2θ diffraction angles: 12.4°, 12.5°, 15.2°, 18.3°, 19.7°, 20.3°, 20.9°, 24.9°, 25.2°, 26.5°, and 30.4°. Full characterization data, including a table of all relevant peaks in the X-ray diffraction pattern, is provided in Example 7. This material 1 The 1 H NMR spectrum is provided in Figure 16.
[0085] Consistent with the crystalline form, nicotine 2,3-dihydroxybenzoate may, in some embodiments, exhibit a relatively sharp melting point. For example, in certain embodiments, nicotine 2,3-dihydroxybenzoate may exhibit a distinct melting point beginning at about 157° C. for the anhydrous form. In certain embodiments, polarized light microscopy of nicotine 3,5-dihydroxybenzoate reveals irregular particles, typically less than about 10 μm. However, it is noted that these particles may exhibit different sizes and / or shapes, which may depend on the method of preparation and / or the ratio of amorphous solid to crystalline solid present in the analyzed sample. In general, nicotine 2,3-dihydroxybenzoate exhibits low hygroscopicity and no change in morphology when exposed to humidity, a desirable property for easy handling.
[0086] In another embodiment, a specific crystalline form of nicotine 1-hydroxy-2-naphthoate (i.e., nicotine xinafoate) has been isolated and characterized. Salts of nicotine 1-hydroxy-2-naphthoate have been previously described. See Dezelic et al., Glasnik Drustva Hemicara Technol. Bosne Hercegoveni et al. (1961), 10:55-62, which is incorporated herein by reference. In accordance with certain embodiments of the present invention, novel crystalline forms of nicotine 1-hydroxy-2-naphthoate are provided and are described according to certain parameters as described herein.
[0087] This novel crystalline form of nicotine 1-hydroxy-2-naphthoate may, in some embodiments, be characterized by an X-ray powder diffraction (XRPD) pattern, as shown in Figure 17. Nicotine 1-hydroxy-2-naphthoate may be described as exhibiting an XRPD pattern having peaks at one or more of the following 2θ diffraction angles: 11.2°, 14.4°, 15.6°, 16.1°, 17.0°, 19.2°, 20.5°, 22.2°, 22.5°, 25.4°, 25.7°, and 27.1°. Full characterization data, including a table of all relevant peaks in the X-ray diffraction pattern, is provided in Example 8. The nicotine 1-hydroxy-2-naphthoate form may be described as exhibiting an XRPD pattern having peaks at one or more of the following 2θ diffraction angles: 15.6°, 16.1°, 20.5°, 22.5°, and 27.1°. Consistent with a crystalline form, this nicotine 1-hydroxy-2-naphthoate form exhibits a discrete melting point with an onset at about 110° C. to about 115° C. (e.g., about 111° C.).
[0088] Advantageously, in certain embodiments, samples of nicotine 1-hydroxy-2-naphthoate are provided that contain at least a certain percentage of the crystalline polymorphic form described herein.For example, in some embodiments, samples of nicotine 1-hydroxy-2-naphthoate are provided that contain at least about 70% by weight, at least about 75% by weight, at least about 80% by weight, at least about 85% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight, at least about 98% by weight, or at least about 99% by weight of the polymorphic form described herein.
[0089] The disclosed nicotine 1-hydroxy-2-naphthoate 1 The H NMR spectrum is provided in Figure 18. This nicotine 1-hydroxy-2-naphthoate form has certain desirable physical properties. For example, the nicotine 1-hydroxy-2-naphthoate disclosed herein exhibits low hygroscopicity and does not change morphology when exposed to humidity, a desirable property for easy handling.
[0090] Those skilled in the art will understand that all diffraction pattern data provided herein should not be considered as absolute, and thus the nicotine salts, co-crystals, and salt co-crystals of the present invention are not limited to particles having XRPD patterns identical to those in Figures 1, 3, 5, 7, 8, 9, 11, 15, and 17. Any nicotine salt, co-crystal, or salt co-crystal having an XRPD pattern substantially identical to that of Figures 1, 3, 5, 7, 8, 9, 11, 15, and 17 is considered to be within the scope of the present invention. Those skilled in the art of X-ray powder diffraction can judge the substantial identity of X-ray powder diffraction patterns. In general, the measurement error of the diffraction angle in an X-ray powder diffractogram is about 2θ=0.5° or less (more preferably about 2θ=0.2° or less), and such degree of measurement error should be taken into consideration when considering the X-ray powder diffraction patterns of Figures 1, 3, 5, 7, 8, 9, 11, 15, and 17, or the peak values provided herein. In other words, the peaks in Figures 1, 3, 5, 7, 8, 9, 11, 15, and 17, and the peak values given throughout the specification, may be taken as being + / - 0.5° or + / - 0.2° in certain embodiments. See Fundamentals of Powder Diffraction and Structural Characterization, Pecharsky and Zavalij, Kluwer Academic Publishers, 2003.
[0091] Other nicotine salts, co-crystals, and salt co-crystals are also encompassed by the present disclosure. For a list of pharma- ceutically acceptable counterions, see Handbook of Pharmaceutical Salts-Properties, Selection, and Use, P. Heinrich Stahl, Camille G. Wermuth (Eds.) VHCA (Verlag Helvetica Chemica Acta - Zurich), Wiley-VCH (New York) 2002, which is incorporated herein by reference. For example, certain coformers useful for reaction with nicotine that may result in the formation of a salt, co-crystal, or salt co-crystal include, but are not limited to, acetic acid, adipic acid, ascorbic acid, capric (decanoic) acid, citric acid, D-glucuronic acid, D-gluconic acid, DL-lactic acid, L-lactic acid, galactaric (mucinic) acid, hippuric (N-benzoylglycine) acid, hydrochloric acid, L-aspartic acid, L-glutamic acid, L-glutaric acid, glycerophosphoric acid, glycolic acid, lauric acid, DL-malic acid, L-malic acid, DL-tartaric acid, L-tartaric acid, palmitic acid, phosphoric acid, sebacic (1,8-octanedicarboxylic) acid, stearic (octadecanoic) acid, succinic acid, sulfuric acid, and thiocyanic acid (HS-CN). Other exemplary coformers for reaction with nicotine that may result in the formation of a salt, co-crystal, or salt co-crystal include, but are not limited to, (+)-camphoric acid, 1,5-naphthalenedisulfonic acid, 1-hydroxy-2-naphthoic (xinafoic) acid, 2,5-dihydroxybenzoic (gentisic) acid, benzenesulfonic acid, benzoic acid, caprylic (octanoic) acid, cyclamic acid, ethanesulfonic acid, fumaric acid, D-glucoheptonic acid, 4-hydroxybenzoic acid, isobutyric acid, ketoglutaric (2-oxo-glutaric) acid, 2-ketobutyric acid, lactobionic acid, maleic acid, malonic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, oleic (Z-octadecanoic) acid, orotic acid, oxalic acid, pamoic acid, pivalic acid, propionic acid, L-pyroglutamic acid, and p-toluenesulfonic acid.
[0092] Certain other types of coformers are generally associated with pharmacological effects and are typically not preferred for the preparation of salts, cocrystals, and salt cocrystals. Although complexes of nicotine with such coformers may not be preferred, in certain special embodiments, they may react with nicotine to form salts, cocrystals, and / or salt cocrystals. Such coformers include, but are not limited to, (1S)-camphor-10-sulfonic acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, N-acetyl-4-aminosalicylic acid, caproic (hexanoic) acid, dichloroacetic acid, hydrobromic acid, DL-mandelic acid, L-mandelic acid, nitric acid, formic acid, salicylic acid, cinnamic (e.g., trans-cinnamic) acid, and undecylenic acid. Other exemplary coformers that may form salts, co-crystals, and / or salt co-crystals with nicotine include, but are not limited to, isothionic acid, lauric (dodecanoic) acid, 2-hydroxybenzoic acid, trans-2-hexanoic acid, trimesic acid, and 5-nitroisophthalic acid.
[0093] Various other coformers can be used to provide nicotine in the form of salt, cocrystal, or cocrystal salt.Exemplary coformers include, but are not limited to, L-proline, tromethamine; urea, xylitol; caffeine; glycine / glycine anhydride; vanillin; methyl 4-hydroxybenzoate (methylparaben); succinamide; L-alanine; mannitol; L-phenylalanine; saccharin; propylparaben; N-methylglucamine; L-tyrosine; gentisic acid; sorbic acid; benzoic acid; L-methionine; maltol; L-lysine, tromethamine; nicotinamide; isonicotinamide; phenylalanine; benzoquinone; terephthalaldehyde; 2,4-dihydroxybenzoic acid; and 4-hydroxybenzoic acid.
[0094] Additional coformers include pyruvic acid, 1-hydroxy-2-naphthoic acid, 4-aminobenzoic acid, 3,5-dihydroxybenzoic acid, 2,3-dihydroxybenzoic acid, 3,4-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, vanillic acid, ethyl vanillin, isonicotinic acid, gallic acid, menthol (e.g., racemic menthol or (-)-menthol), paracetamol, aspirin, ibuprofen, naproxen, ketoprofen. , flurbiprofen, glucose, serine, malic acid, acetamide, sulfacetamide, benzoic acid, 4-aminobenzoic acid, creatine, 2-hydroxyethanesulfonic acid, clofibric acid, taurine (tauric acid), iproniazid, L-histidine, L-arginine, L-asparagine, glutamine, L-cysteine, alanine, valine, isoleucine, leucine, morpholine, threonine, and N-methylglucamine.
[0095] Certain exemplary coformers that can provide nicotine salts, co-crystals, or co-crystal salts are sugar-based acids (i.e., monosaccharides having a carboxyl group). Representative types of sugar acids include aldonic acids (e.g., glyceric acid, xylonic acid, gluconic acid, and ascorbic acid), urosonic acids (e.g., neuraminic acid and ketodeoxyoctulosonic acid), uronic acids (e.g., glucuronic acid, galacturonic acid, and iduronic acid), and aldonic acids (e.g., tartaric acid, meso-galactaric acid / mucinic acid, and D-glucaric acid / saccharic acid). In a preferred embodiment, the one or more coformers used to provide a nicotine salt, co-crystal, or salt co-crystal according to the present disclosure is aldaric acid, and in a particularly preferred embodiment, the aldaric acid is mucic acid ((2S,3R,4S,5R)-2,3,4,5-tetrahydroxyhexanedioic acid, also known as galactaric acid or meso-galactaric acid).
[0096] Other exemplary coformers capable of providing nicotine cocrystals, salts, or cocrystal salts are polyfunctional aromatic acids. Polyfunctional aromatic acids often contain a substituted or unsubstituted phenyl group as the aromatic component, but may alternatively contain another aromatic moiety, such as pyridine, pyrazine, imidazole, pyrazole, oxazole, thiophene, naphthalene, anthracene, and phenanthrene. The substituents on the optionally substituted aromatic acids may be any type of substituent, including halo (e.g., Cl, F, Br, and I); alkyl, alkyl halides (e.g., CF 3 , 2-Br-ethyl, CH 2 F, C.H. 2 Cl, CH 2 CF 3 , or CF 2 CF 3 ); alkenyl, hydroxyl; amino; carboxylate; carboxamide; alkylamino; arylamino; alkoxy; aryloxy; nitro; azido; cyano; thio; sulfonic acid; sulfate; phosphoric acid; phosphate; and phosphate groups. Exemplary polyfunctional aromatic acids include, for example, Substituted and unsubstituted aromatic dicarboxylic acids (e.g., 1,2-benzenedicarboxylic acid (phthalic acid), 1,3-benzenedicarboxylic acid (isophthalic acid), 1,4-benzenedicarboxylic acid (terephthalic acid), 2-iodo-1,3-benzenedicarboxylic acid, 2-hydroxy-1,4-benzenedicarboxylic acid, 2-nitro-1,4-benzenedicarboxylic acid, 3-fluoro-1,2-benzenedicarboxylic acid, 3-amino-1,2-benzenedicarboxylic acid, 3-nitro-1,2-benzenedicarboxylic acid, 4-bromo-1,3-benzenedicarboxylic acid, 4-hydroxy-1,3-benzenedicarboxylic acid, 4-amino-1,2-benzenedicarboxylic acid, carboxylic acids, 4-nitro-1,2-benzenedicarboxylic acid, 4-sulfo-1,2-benzenedicarboxylic acid, 4-amino-1,3-benzenedicarboxylic acid, 5-bromo-1,3-benzenedicarboxylic acid, 5-hydroxy-1,3-benzenedicarboxylic acid, 5-amino-1,3-benzenedicarboxylic acid, 5-nitro-1,3-benzenedicarboxylic acid, 5-ethynyl-1,3-benzenedicarboxylic acid, 5-cyano-1,3-benzenedicarboxylic acid, 5-nitro-1,3-benzenedicarboxylic acid, 2,5-hydroxy-1,4-benzenedicarboxylic acid, and 2,3,5,6-tetrafluoro-1,4-benzenedicarboxylic acid; Substituted and unsubstituted hydroxybenzoic acids (e.g., 2-hydroxybenzoic acid (salicylic acid), 3-hydroxybenzoic acid, 4-hydroxybenzoic acid, 2-methyl-4-hydroxybenzoic acid, 3-tert-butyl-4-hydroxybenzoic acid, 4-ethoxy-2-hydroxybenzoic acid, 3-chloro-5-hydroxybenzoic acid, 5-chloro-2-hydroxybenzoic acid, 3-bromo-4-hydroxybenzoic acid, 3-bromo-5-hydroxybenzoic acid, 4-bromo-2-hydroxybenzoic acid, 5-bromo-2-hydroxybenzoic acid, 2-fluoro-5-hydroxybenzoic acid, Acid, 3-fluoro-4-hydroxybenzoic acid, 3-fluoro-2-hydroxybenzoic acid, 3-fluoro-5-hydroxybenzoic acid, 2-fluoro-6-hydroxybenzoic acid, 4-fluoro-3-hydroxybenzoic acid, 2-fluoro-4-hydroxybenzoic acid, 5-fluoro-2-hydroxybenzoic acid, 2-amino-3-hydroxybenzoic acid, 2-amino-5-hydroxybenzoic acid, 3-amino-2-hydroxybenzoic acid, 3-amino-4-hydroxybenzoic acid, 3-amino-5-hydroxybenzoic acid, 4-amino-2-hydroxybenzoic acid, 4-amino 5-amino-2-hydroxybenzoic acid (mesalamine), 5-aminoethyl-2-hydroxybenzoic acid, 4-formyl-3-hydroxybenzoic acid, 3-formyl-4-hydroxybenzoic acid, 5-(acetylamino)-2-hydroxybenzoic acid, 4-nitro-2-hydroxybenzoic acid, 3,5-diethyl-4-hydroxybenzoic acid, 3,5-di-tert-butyl-4-hydroxybenzoic acid, 3,5-diisopropyl-2-hydroxybenzoic acid, 3,4-dimethoxy-4-hydroxybenzoic acid (syringic acid), 3,5-di- 2,3,4,6-tribromo-2-hydroxybenzoic acid, 3,5-dichloro-4-hydroxybenzoic acid, 3,6-dichloro-2-hydroxybenzoic acid, 2,3-difluoro-4-hydroxybenzoic acid, 3,4-difluoro-2-hydroxybenzoic acid, 3,5-dibromo-2-hydroxybenzoic acid, 3,5-diiodo-2-hydroxybenzoic acid, 4-amino-5-chloro-2-hydroxybenzoic acid, 3,5-dinitro-2-hydroxybenzoic acid, 2,4,6-tribromo-2-hydroxybenzoic acid, 2,3,5,6-tetrafluoro-4-hydroxybenzoic acid, and 2,3,4,5-Tetrafluoro-6-hydroxybenzoic acid); Substituted and unsubstituted dihydroxybenzoic acids (e.g., 2,3-dihydroxybenzoic acid (pyrocatechuic acid / lactic acid), 2,4-dihydroxybenzoic acid (β-resorcylic acid), 2,5-dihydroxybenzoic acid (gentisic acid / hydroquinone carboxylic acid), 2,6-dihydroxybenzoic acid (γ-resorcylic acid), 3,4-dihydroxybenzoic acid (protocatechuic acid), 3,5-dihydroxybenzoic acid (α-resorcylic acid), 4-hydroxy-3-methoxybenzoic acid (ba diphosphoric acid), 6-methyl-2,4-dihydroxybenzoic acid (orselenic acid), 4-bromo-3,5-dihydroxybenzoic acid, 5-bromo-2,4-dihydroxybenzoic acid, 5-bromo-3,4-dihydroxybenzoic acid, 6-carboxymethyl-2,3-dihydroxybenzoic acid, 3,5-dibromo-2,4-dihydroxybenzoic acid, 3,5-dichloro-2,6-dihydroxybenzoic acid, and 5-amino-3-chloro-2,4-dihydroxybenzoic acid); and Substituted and unsubstituted trihydroxybenzoic acids (e.g., 2,3,4-trihydroxybenzoic acid, 2,4,5-trihydroxybenzoic acid, 2,4,6-trihydroxybenzoic acid (phloroglucinol carboxylic acid), and 3,4,5-trihydroxybenzoic acid (gallic acid)). Substituted and unsubstituted aromatic tricarboxylic acids (e.g., 1,2,3-benzenetricarboxylic acid, 1,2,4-benzenetricarboxylic acid (trimellitic acid); and Substituted and unsubstituted aromatic tetracarboxylic acids can be used, such as 1,2,3,4-benzenetetracarboxylic acid (mellophanic acid) and 1,2,4,5-benzenetetracarboxylic acid (pyromellitic acid).
[0097] Other coformers useful in certain embodiments are flavor acids, including, but not limited to, 3-hydroxy-2-oxopropionic acid, 2-oxobutyric acid (2-ketobutyric acid), 3-methyl-2-oxobutanoic acid, 3-methyl-2-oxopentanoic acid, 4-methyl-2-oxopentanoic acid, and 2-oxopentanedioic acid. Additional coformers, such as 2-oxo-3-phenylpropionic acid, 5-oxooctanoic acid, and 5-oxodecanoic acid, may have higher molecular weights.
[0098] It should be noted that certain coformers described herein may contain one or more chiral centers, which may be in either the (R) or (S) configuration, or may include mixtures thereof. As a result, various diastereomeric nicotine salts, cocrystals, and salt cocrystals may be provided in accordance with the present disclosure. The present invention includes such diastereomers either individually or admixed in any ratio. Certain coformers described herein may be geometric isomers, including but not limited to cis and trans isomers across a double bond. The present invention includes all nicotine salts, cocrystals, and salt cocrystals prepared with such isomers, which may be provided in the form of pure isomers or in admixtures with other isomers.
[0099] The method(s) by which the nicotine salts, co-crystals, and salt co-crystals described herein may be produced may vary. In some embodiments, the nicotine salts, co-crystals, and salt co-crystals are prepared without the use of solvents (or with a minimal amount of solvent). In so-called "solvent-free" methods, a solvent is generally not used, although it is noted that one or more solvents may be optionally added to the mixture (typically in small amounts) to facilitate the formation of the nicotine salt, co-crystal, or salt co-crystal. In certain embodiments, the components (i.e., nicotine and one or more co-formers) are combined in the absence of a solvent to form a slurry. The solids containing the nicotine salt, co-crystal, and / or salt co-crystal may be isolated therefrom via common methods (e.g., filtration). The slurry may optionally be heated, whereby the nicotine and one or more co-formers interact in molten form to produce the salt, co-crystal, or salt co-crystal. In certain embodiments, a physical method is used to combine the components (i.e., nicotine and one or more co-formers). For example, nicotine and the coformer(s) may be mechanically ground together (e.g., using a mortar and pestle, a ball mill, or a vibratory mill).
[0100] In certain embodiments, the combination of nicotine and coformer in a given solvent (or solvents) and evaporation of the solvent can result in the desired nicotine salt, co-crystal, or salt co-crystal. Typically, in such methods, nicotine and coformer are provided in stoichiometric amounts (i.e., no excess nicotine or co-former is added). In such methods, the choice of solvent is important because the solvent (or solvents) in which the reaction is carried out can affect the intermolecular interactions. Evaporation of the solvent can be carried out at a controlled rate (e.g., slowly) to facilitate the preparation of crystals of a single nicotine salt, co-crystal, or salt co-crystal for characterization. For example, evaporation of the solvent can be carried out over hours, days, weeks, or months.
[0101] In some embodiments, the combination of nicotine and a coformer in a given solvent (or solvents) and the addition of a non-solvent can result in the desired nicotine salt, co-crystal, or salt co-crystal. Exemplary solvents and non-solvents that can be used to prepare nicotine salts, co-crystals, and salt co-crystals include, but are not limited to, water, alcohols (e.g., methanol, ethanol, n-butanol, isopropanol), ethers (e.g., diethyl ether, petroleum ether), ethyl acetate, acetone, tetrahydrofuran, methylene chloride, chloroform, alkanes (e.g., pentane, hexane, heptane, octane, nonane, cyclohexane), benzene, toluene, 1,4-dioxane, and combinations thereof. In some embodiments, nicotine salts, co-crystals, and salt co-crystals can be prepared in supercritical fluids.
[0102] In other embodiments, the desired nicotine salt, co-crystal, or salt co-crystal can be prepared by freeze-drying a solution of nicotine and one or more coformers, followed by aging. For example, a solution may be prepared, frozen, and freeze-dried to remove the solvent. An aging solvent is then added, and the resulting solid can be obtained by conventional methods (e.g., filtration). The aging solvent includes, but is not limited to, the types of solvents described above.
[0103] The methods of producing nicotine salts, co-crystals, and salt co-crystals described herein, in some embodiments, employ an excess of a coformer component. In such embodiments, it may be advantageously possible to purify the resulting salt, co-crystal, or salt co-crystal by removing therefrom the excess coformer (i.e., the coformer is not part of the structure of the salt, co-crystal, or salt co-crystal).
[0104] In certain embodiments, exemplary methods for salt, co-crystal, or salt co-crystal formation that may be applicable to the preparation of the nicotine salts, co-crystals, and salt co-crystals described herein are described in, for example, U.S. Pat. Nos. 8,513,236 (Schultheiss et al.); 8,470,832 (George et al.); 8,466,280 (Grunenberg et al.); 8,415,507 (Schultheiss et al.); 8,350,085 (Childs); and 8,241,371 (Patent Publication No. 20050222222). (Hanna et al.); No. 8,212,079 (Childs); No. 8,173,625 (Brittain et al.); No. 8,163,790 (Childs); No. 8,197,592 (Imamura et al.); No. 8,058,437 (Bauer et al.); No. 7,935,817 (Blazecka et al.); No. 7,927,613 (Almarsson et al.); No. 7,452,555 (Childs); No. 7,008,742 (Molaire); U.S. Patent Application Publication No. 2013 No. 2013 / 0072440 (Dokou et al.); No. 2013 / 0040970 (Cosgrove et al.); No. 2012 / 0258170 (Kruthiventi et al.); No. 2012 / 0028998 (Sansone et al.); No. 2012 / 0028930 (Kalofonos et al.); No. 2012 / 0022117 (Gruss et al.); No. 2011 / 0257340 (Childs); No. 2011 / 0251426 (Hann a et al.); 2011 / 0236478 (Dokou et al.); 2011 / 0152266 (Grunenberg et al.); 2010 / 0204204 (Zaworotko et al.); 2008 / 0280858 (Hanna et al.), 2007 / 0287194 (Childs et al.); 2003 / 0224006 (Zaworotko et al.); and 2002 / 0048610 (Cima et al.), all of which are incorporated herein by reference in their entireties.Other references providing exemplary means for the formation of certain nicotine salts include M. Dezelic and B. Nikolin, "Nicotine Compounds with Aromatic Acids. Part II.," Glasnik Drustva Hemicara Technol. NR Bosne I Hercegovine, Sarajevo, 10 (1961) 55-62, and M. Dezelic and D. Tomic, "Nicotine Compounds with Aromatic Acids," Kem. Vjestnik 17 (1943): 39-57, which are incorporated herein by reference.
[0105] For the preparation of nicotine mucate salt, in one embodiment, the salt is provided by combining the acid and nicotine in the absence of a solvent. In some embodiments, excess nicotine is added to the reaction mixture, and the excess nicotine is advantageously removed (e.g., by vacuum and / or by washing / filtration with, for example, THF, heptane, and / or EtOAc).
[0106] For the preparation of the novel polymorphic forms of nicotine 4-acetamidobenzoate described herein, in one embodiment, the salt is provided by combining the acid and nicotine in the absence of a solvent. For example, in one embodiment, 4-acetamidobenzoic acid is suspended in a minimum amount of nicotine required to produce a moving slurry, which is stirred / shaken to form the nicotine salt. In another embodiment, a solvent (e.g., THF) is used to facilitate salt formation. For example, 4-acetamidobenzoic acid can be dissolved in THF, nicotine can be added thereto, and the resulting mixture can be stirred / shaken to produce the salt. The solvent can be removed (e.g., by evaporation) to provide the desired nicotine 4-acetamidobenzoate form. In some embodiments, the solid is washed, for example, with THF, heptane, and / or EtOAc.
[0107] For the preparation of the novel polymorphic forms of nicotine gentisate described herein, in one embodiment, the salt is provided by combining the acid and nicotine in the absence of a solvent. For example, in one embodiment, gentisic acid is suspended in a minimum amount of nicotine required to produce a moving slurry, which is stirred / shaken to form the nicotine salt. In another embodiment, a solvent (e.g., THF) is used to facilitate salt formation. For example, 4-acetamidobenzoic acid can be dissolved in THF, nicotine can be added thereto, and the resulting mixture can be stirred / shaken to produce the salt. The solvent can be removed (e.g., by evaporation) to provide the desired nicotine 4-acetamidobenzoate. In some embodiments, the solid is washed, for example, with THF and / or heptane.
[0108] For the preparation of nicotine 3,5-dihydroxybenzoate as described herein, in one embodiment, the salt is provided by combining the acid and nicotine in a solvent (e.g., THF or acetone). For example, 3,5-dihydroxybenzoic acid, followed by nicotine, can be dissolved in THF or acetone, and the resulting mixture can be stirred / shaken to obtain a solid salt. The solvent can be removed (e.g., by evaporation) and optionally washed as described above (e.g., with heptane) to provide the desired 3,5-dihydroxybenzoate. In certain embodiments, this method provides an anhydrous form, which can be easily converted to a hydrated form, such as the dihydrated form described herein (e.g., by exposing the anhydrous form to elevated humidity levels, e.g., 96% relative humidity at 25°C for 16 hours). It is understood that variable amounts of humidity, temperature, and time can result in a hydrated (e.g., dihydrate) form.
[0109] For the preparation of nicotine 2,3-dihydroxybenzoate as described herein, in one embodiment, the salt can be prepared in pure nicotine (in the absence of a solvent). In another embodiment, a solvent can be used. For example, 2,3-dihydroxybenzoic acid, followed by nicotine, can be dissolved in THF, and the resulting mixture can be stirred / shaken to obtain a solid salt. The solvent can be removed (e.g., by evaporation) and optionally washed as described above (e.g., with heptane) to provide the desired nicotine 2,3-dihydroxybenzoate.
[0110] For the preparation of the nicotine 1-hydroxy-2-naphthoate forms described herein, in one embodiment, the salt can be prepared in pure nicotine (in the absence of a solvent). In another embodiment, a solvent can be used. For example, 1-hydroxy-2-naphthoic acid can be dissolved in THF, followed by nicotine, and the resulting mixture can be stirred / shaken to obtain a solid salt. The solvent can be removed (e.g., by evaporation) and optionally washed as described above (e.g., with heptane) to provide the desired polymorphic crystalline form of nicotine 1-hydroxy-2-naphthoate.
[0111] Desirably, single crystal X-ray diffraction (SCXRD) can be used in some embodiments to determine the composition of the solids (i.e., nicotine salts, co-crystals, and salt co-crystals). However, suitable X-ray quality crystals cannot always be easily produced. Thus, a variety of other solid-state spectroscopic techniques can be used, including, but not limited to, X-ray powder diffraction (XRPD), Raman spectroscopy, FTIR spectroscopy, vibrational spectroscopy, polarized light microscopy (PLM), and solid-state NMR. The nicotine salts, co-crystals, and salt co-crystals described herein can be analyzed by, for example, 13 C NMR and 1 1 H NMR and other techniques (in a suitable solvent, e.g., D 2 O or DMSO-d 6in water) to assess chemical structure, gravimetric vapor sorption (GVS) to assess hygroscopicity, thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) to assess thermal properties, and / or chromatography (e.g., HPLC) in a suitable solvent to assess purity. The products described herein can be further analyzed via Karl Fischer titration to determine water content.
[0112] It should be noted that in some cases, it is difficult to distinguish between cocrystals and salts. Typically, distinguishing salts from cocrystals requires evidence of proton transfer, which may not be directly identified using single crystal X-ray diffraction. In other words, distinguishing salts from cocrystals generally requires evidence of ionic interactions, as opposed to simply non-ionic interactions. Thus, although the novel compositions described herein are described as salts, it should be noted that in some embodiments, it is not known whether a given product exists in salt, cocrystal, or salt cocrystal form, or in some kind of intermediate form (e.g., a proton is not transferred to the base site, but may exist in the space between the donor coformer and the acceptor).
[0113] The nicotine salts, co-crystals, and salt co-crystals described herein can be incorporated into a variety of products, including tobacco-containing products. The important characteristics of the nicotine salts, co-crystals, and salt co-crystals for use in different types of products differ, as detailed below.
[0114] The nicotine salts, cocrystals, and salt cocrystals provided herein may, in some embodiments, be used as compositions in the manufacture of smoking articles. For example, the salts, cocrystals, and salt cocrystals prepared according to the present invention may be mixed with casing materials and applied to tobacco as a casing ingredient or as a top dressing. Still further, the salts, cocrystals, and salt cocrystals of the present disclosure may be incorporated into cigarette filters (e.g., filter plugs, plug wraps, or tipping papers) or into cigarette wrappers, preferably on the inner surface, during the cigarette manufacturing process. See, for example, the description and references of tobacco isolates used in smoking articles described in U.S. Patent Publication No. 2012 / 0192880 (Dube et al.), which is incorporated herein by reference. Representative tobacco blends, non-tobacco components, and representative cigarettes made therefrom are also described in the Dube et al. references above.
[0115] Typically, the amount of nicotine salt, co-crystal, or salt co-crystal incorporated into a smoking article is sufficient to provide a desired amount of free nicotine in mainstream smoke produced therefrom. For example, in some embodiments, a smoking article may provide an amount of nicotine of about 0.1 mg to about 10 mg, about 0.5 mg to about 9 mg, or about 1 mg to about 8 mg. Thus, the amount of nicotine salt, co-crystal, or salt co-crystal incorporated into a smoking article may be, for example, an amount sufficient to produce these amounts of nicotine when the article is used.
[0116] Referring to FIG. 19, a smoking article 10 is shown having certain representative components of a smoking article that may contain the formulation of the present invention, in the form of a cigarette. The cigarette 10 includes a generally cylindrical rod 12 of filler or roll of smokable filler material (e.g., about 0.3 g to about 1.0 g of smokable filler material, e.g., tobacco material) contained in a circumscribing wrapping material 16. The rod 12 is conventionally referred to as a "tobacco rod." The ends of the tobacco rod 12 are open to expose the smokable filler material. The cigarette 10 is shown as having one optional band 22 (e.g., a printed coating including a film-forming agent, such as starch, ethyl cellulose, or sodium alginate) applied to the wrapping material 16, which band circumscribing the cigarette in a direction perpendicular to the longitudinal axis of the cigarette. The band 22 may be printed on the inner surface of the wrapping material (i.e., facing the smokable filler material) or, less preferably, on the outer surface of the wrapping material.
[0117] The tobacco rod 12 terminates at a lighting end 18 and at a mouth end 20 has a filter element 26 positioned thereon. The filter element 26 is positioned adjacent one end of the tobacco rod 12 such that the filter element and the tobacco rod are axially aligned in an end-to-end relationship, preferably adjacent one another. The filter element 26 may have a generally cylindrical shape and its diameter may be essentially equal to the diameter of the tobacco rod. The ends of the filter element 26 permit the passage of air and smoke therethrough.
[0118] Ventilated or air diluted smoking articles may be provided with optional air dilution means such as a series of perforations 30 each extending through the tipping material and plug wrap. The optional perforations 30 may be made by a variety of techniques known to those skilled in the art, such as laser drilling techniques. Alternatively, so-called off-line air dilution techniques may be used (e.g., by using a porous paper plug wrap and pre-perforated tipping paper). The salts of the present invention may be incorporated into any of the components of the smoking article, including but not limited to, as a component of the tobacco filler, as a component of the wrapping paper (e.g., included in the paper or coated on the inside or outside of the paper), as an adhesive, as a filter element component, and / or within a capsule located in any area of the smoking article.
[0119] The temperature at which nicotine, the coformer component(s), and any degradation products thereof are released from the nicotine salt, co-crystal, or salt co-crystal may be a relevant consideration in the design of a smoking article. It is typically important that nicotine is released from the salt, co-crystal, or salt co-crystal at the burning temperature of the smoking article (i.e., that nicotine is transferred to mainstream smoke and delivered to the user). In some embodiments, it may also be important that certain undesirable coformers and / or their degradation products are not transferred to mainstream smoke (and delivered to the user). The relevant temperatures may vary slightly depending on the specific location(s) of the salt, co-crystal, or salt co-crystal within the smoking article. For example, in certain embodiments, the temperature at which the smoking article is burned (and therefore the temperature to which the salt is exposed) is at least about 100°C to at least about 200°C, or at least about 500°C, in certain regions of the smoking article, from about 100°C to about 500°C, and in other regions of the smoking article, from about 600°C to about 900°C. These considerations can influence the selection of a suitable salt, co-crystal, or salt co-crystal for a particular application.
[0120] In other embodiments, the nicotine salts, cocrystals, and salt cocrystals disclosed herein may be incorporated into smokeless tobacco products. Exemplary smokeless tobacco compositions according to the present invention may have a wide variety of formats and configurations, resulting in different composition characteristics, properties, behavior, density, shape, form, size, and weight. In some embodiments, the nicotine salts, cocrystals, and salt cocrystals disclosed herein may be incorporated into smokeless tobacco products such as loose moist snuff (e.g., snus); loose dry snuff; chewing tobacco; pelleted tobacco pieces; extruded or formed tobacco strips, pieces, rods, cylinders, or sticks; finely divided powders; finely divided or pulverized agglomerates of powdered pieces and ingredients; flake-like pieces; molded tobacco pieces; gums; rolls of tape-like films; water-soluble or water-dispersible films or strips; meltable compositions; lozenges; drops; and capsule-like materials having an outer shell and an inner region. Exemplary composition shapes may be generally spherical, cylindrical (e.g., ranging from the general shape of a flattened disk to the general shape of a relatively long, thin stick), helical, oblate, square, rectangular, etc., or the compositions may have the form of beads, granular powders, crystalline powders, capsules, films, strips, gels, etc. The shapes of the compositions may resemble various pill, tablet, lozenge, capsule, and caplet type products. Various types of smokeless tobacco products are described or referenced in U.S. Patent Publication Nos. 2013 / 0206150 (Duggins et al.); 2013 / 0074855 (Holton, Jr.); 2012 / 0118310 (Cantrell et al.); 2012 / 0138073 (Cantrell et al.); 2012 / 0138074 (Cantrell et al.); and 2012 / 0152265 (Dube et al.), all of which are incorporated herein by reference.
[0121] With reference to Figure 20, an exemplary snus-type tobacco product is shown that includes one or more nicotine salts, co-crystals, or salt co-crystals according to the present disclosure. Specifically, Figure 20 shows a smokeless tobacco product 40 having a water-permeable outer pouch 42 that contains a smokeless tobacco composition 44. Any of the components of the tobacco product may include one or more nicotine salts, co-crystals, or salt co-crystals according to the present disclosure (e.g., the inside or outside of the pouch liner or a portion of the smokeless tobacco composition contained therein).
[0122] Other exemplary smokeless tobacco products into which the salts, cocrystals, and salt cocrystals described herein may be incorporated may have the form of gums, lozenges, tablets, microtabs, or other tablet-type products, see, for example, U.S. Patent Nos. 4,967,773 (Shaw); 5,110,605 (Acharya); 5,733,574 (Dam); 6,280,761 (Santus); 6,676,959 (Andersson et al.); 6,248,760 (Wilhelmsen); and 7,374,779; U.S. Patent Publication Nos. 2013 / 0074855 and 2013 / 0078307 (Holton, Jr.); and 2001 / 0016593 (Wilhelmsen), all of which are incorporated herein by reference. see, for types of nicotine-containing lozenges, lozenge formulations, lozenge formats and configurations, lozenge characteristics, and techniques for formulating or manufacturing lozenges, see Limsen; 2004 / 0101543 (Liu et al.); 2006 / 0120974 (Mcneight); 2008 / 0020050 (Chau et al.); 2009 / 0081291 (Gin et al.); and 2010 / 0004294 (Axelsson et al.); and 2013 / 0312774 (Holton, Jr.).
[0123] One representative type of smokeless tobacco product comprising one or more of the nicotine salts, co-crystals, or salt co-crystals described herein is a lozenge, for example, as substantially described in U.S. Patent Application Publication Nos. 2013 / 0312774, 2013 / 0074856, and 2013 / 0074855 (all to Holton, Jr.), which are incorporated herein by reference. Such lozenges may contain a majority of one or more sugar alcohols (e.g., isomalt and maltitol syrup) in an amount of, for example, at least about 50% by weight, at least about 70% by weight, at least about 80% by weight, or at least about 90% by weight, in addition to one or more nicotine salts, co-crystals, or salt co-crystals. Other ingredients of particular interest in such lozenge products include, but are not limited to, salts (e.g., NaCl), sweeteners (e.g., sucralose), and one or more flavoring agents.
[0124] The amount of nicotine salt, co-crystal, or salt co-crystal incorporated into a smokeless tobacco composition may vary and may depend, in part, on the particular type of smokeless tobacco composition. Obviously, the amount of a given nicotine salt, co-crystal, or salt co-crystal incorporated into a product will depend on the desired nicotine content of the product and may be calculated based on the mass of the coformer and the stoichiometry of the salt, co-crystal, or salt co-crystal. Exemplary amounts include from about 0.1% by weight of the consumable material to about 10% by weight of the consumable or inhalable material. For example, for a lozenge, the amount of nicotine salt, co-crystal, or salt co-crystal is at least about 0.5%, typically at least about 1% by weight, often at least about 1.5% by weight, often at least about 2% by weight, often at least about 2.5% by weight, and frequently at least about 3% by weight of the product, e.g., from about 0.5% by weight to about 10% by weight, including from about 1% by weight to about 5% by weight. The amount of nicotine salt, co-crystal, or salt co-crystal can be determined based on the desired nicotine content in the lozenge.
[0125] A variety of other substances may be added to the smokeless tobacco compositions containing the nicotine salts, co-crystals, or salt co-crystals of the invention. For example, excipients such as fillers or carriers for the active ingredient (e.g., calcium polycarbophil, microcrystalline cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, corn starch, silicon dioxide, calcium carbonate, lactose, and starches, including potato starch and maize starch), thickeners, film formers and binders (e.g., hydroxypropyl cellulose, hydroxypropyl methylcellulose, acacia, sodium alginate, gum arabic, lecithin, xanthan gum, and gelatin), anti-adherents (e.g., talc), lubricants (e.g., colloidal silica), humectants (e.g., glycerin), preservatives and antioxidants (e.g., sodium benzoate and ascorbyl palmitate), surfactants (e.g., polysorbate 80), dyes or pigments (e.g., titanium dioxide or D&C Yellow No. 10), and lubricants or processing aids (e.g., calcium stearate or magnesium stearate) are added to the composition in certain embodiments. Other exemplary types of ingredients include salts (e.g., sodium chloride, potassium chloride, sodium citrate, potassium citrate, sodium acetate, potassium acetate, and the like), natural sweeteners (e.g., fructose, sucrose, glucose, maltose, vanillin, ethyl vanillin glucoside, mannose, galactose, lactose, and the like), artificial sweeteners (e.g., sucralose, saccharin, aspartame, acesulfame K, neotame, and the like), pH adjusters or buffers (e.g., metal hydroxides, preferably alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, as well as other alkali metal buffers such as metal carbonates, preferably potassium carbonate or sodium carbonate, or metal bicarbonates such as sodium bicarbonate, and the like), foaming materials such as certain acid / base combinations, oral care additives (e.g., thyme oil, eucalyptus oil, and zinc), preservatives (e.g., sodium sorbate, and the like), syrups (e.g., honey, high fructose corn syrup, and the like), and mixtures thereof.In certain embodiments, the smokeless tobacco composition may include a lipid component that provides a meltable composition that dissolves (as opposed to simply melting) in the oral cavity, such as the compositions described in U.S. Patent Publication No. 2012 / 0037175 (Cantrell et al.), which is incorporated herein by reference. Exemplary encapsulation additives that may be included in the smokeless tobacco products disclosed herein are described, for example, in WO 2010 / 132444 (Atchley), which is already incorporated herein by reference. See also the smokeless tobacco components described in U.S. Patent Publication Nos. 2012 / 0055494 (Hunt et al.) and 2012 / 0199145 (Byrd et al.), which are incorporated herein by reference.
[0126] The manner and methods used to formulate and manufacture smokeless tobacco products may vary. Raw materials including the nicotine salts, co-crystals, or salt co-crystals described herein may be compounded and processed into the desired composition by techniques such as extrusion, pressing, molding, spraying, etc. It should be noted that certain considerations, as described above for electronic smoking articles, are not relevant in the setting of smokeless tobacco products. For example, nicotine salts, co-crystals, or salt co-crystals useful in smokeless tobacco products do not need to transfer to an aerosol form at a given temperature. In smokeless tobacco products, the main consideration is that the nicotine salts, co-crystals, or salt co-crystals contained therein may provide nicotine when the smokeless tobacco product is placed in the user's mouth (i.e., sometime during the residence of the smokeless tobacco product in the user's mouth). Thus, a certain nicotine salt, co-crystal, or salt co-crystal that is useful for one type of tobacco product may not be useful for others.
[0127] In certain embodiments, the nicotine salts, co-crystals, and salt co-crystals provided in accordance with the present disclosure are incorporated into electronic smoking articles. An exemplary embodiment of an electronic smoking article 200 incorporating a nicotine salt, co-crystal, or salt co-crystal in accordance with the present disclosure is shown in FIG. 21. As shown therein, a control body 202 may be formed from a housing 201 that may include a control component 206, a flow sensor 208, a battery 210, and an LED 212. The electronic smoking article may also include a cartridge 204 that may be formed from a housing 203 that encloses a reservoir 244 in fluid communication with a transport element 236 adapted to wick or otherwise transport an aerosol precursor stored in the reservoir to a heater 234 (e.g., a resistive heating wire that may be wound around at least a portion of the transport element). Exemplary reservoirs and transport elements are disclosed in U.S. Patent Publication No. 2014 / 0261487 (Chapman et al.), and exemplary heaters are disclosed in U.S. Patent Publication No. 2014 / 0157583 (Ward et al.), the disclosures of which are incorporated herein by reference in their entireties. An opening 228 can be present in the cartridge housing 203 at its mouth end 205 to permit exit of the formed aerosol from the cartridge 204. Such components are representative of components that may be present in the control body and / or cartridge, and are not intended to limit the scope of components encompassed by the present disclosure.
[0128] The cartridge 204 may be adapted to engage with the control body 202 through a press-fit engagement between the protrusion 224 of the control body and the receptacle 240 of the cartridge. Such engagement may facilitate a stable connection between the control body 202 and the cartridge 204, as well as establish an electrical connection between the battery 210 and the control component 206 in the control body and the heater 234 in the cartridge. Other types of connections (e.g., threaded connections) are also encompassed. The electronic smoking article 200 may be adapted for puffing, for example, provided in a coupler as described in U.S. Patent Publication No. 2014 / 0261408 (DePiano et al.), the disclosure of which is incorporated herein by reference in its entirety. The cartridge 204 may include one or more electronic components 250, which may include ICs, memory components, sensors, and the like. The electronic components 250 may be adapted to communicate with the control component 206 to provide input. See, for example, U.S. Patent Publication Nos. 2014 / 0096781 (Sears et al.) and 2014 / 0096782 (Ampolini et al.), the disclosures of which are incorporated by reference in their entireties.
[0129] Electronic smoking articles can include various combinations of components useful in forming electronic aerosol delivery devices, such as the following: a reservoir and heater system for controllable delivery of multiple aerosolizable materials as disclosed in U.S. Patent Publication No. 2014 / 0000638 (Sebastian et al.); a microheater as disclosed in U.S. Patent Publication No. 2014 / 0060554 (Collett et al.); a carbon-based cartridge and components thereof as disclosed in U.S. Patent Publication No. 2013 / 0255702 (Griffith, Jr. et al.); a carbon-based cartridge and components thereof as disclosed in U.S. Patent Publication No. 2014 / 0060555 (Chang et al.); aerosol precursor transport elements, such as those disclosed in U.S. Patent Publication No. 2014 / 0209105 (Sears et al.); charging components, such as adapters, as disclosed in U.S. Patent Publication No. 2014 / 0261495 (Novak, III et al.); vibration components, such as those disclosed in U.S. Patent Publication No. 2015 / 0020825 (Galloway et al.); and batteries, such as those disclosed in U.S. Patent Publication No. 2010 / 0028766 (Peckerar et al.).
[0130] Representative types of aerosol precursor components and formulations are also described and characterized in U.S. Pat. No. 7,217,320 (Robinson et al.), and U.S. Patent Publication Nos. 2013 / 0008457 (Zheng et al.); 2013 / 0213417 (Chong et al.); 2014 / 0060554 (Collett et al.); 2015 / 0020823 (Lipowicz et al.); and 2015 / 0020830 (Koller), as well as WO 2014 / 182736 (Bowen et al.), the disclosures of which are incorporated herein by reference. Other aerosol precursors that can be used include the aerosol precursors incorporated in the VUSE® products by RJ Reynolds Vapor Company, the BLU™ products by Lorillard Technologies, the MISTIC MENTHOL products by Mistic Ecigs, and the VYPE products by CN Creative Ltd. Also desirable are so-called "smoke juices" for electronic cigarettes available from Johnson Creek Enterprises LLC.
[0131] In certain embodiments, the aerosol precursor comprises a nicotine salt, co-crystal, or salt co-crystal disclosed herein. In one embodiment, the aerosol precursor composition may comprise, for example, a polyhydric alcohol (e.g., glycerin, propylene glycol, or a combination thereof), water, a nicotine salt, co-crystal, or salt co-crystal described herein, and a flavoring material (e.g., menthol). Exemplary flavorings include vanillin, ethyl vanillin, cream, tea, coffee, fruit (e.g., apple, cherry, strawberry, peach, and citrus flavors including lime and lemon), maple, menthol, mint, peppermint, spearmint, wintergreen, nutmeg, clove, lavender, cardamom, ginger, honey, anise, sage, cinnamon, sandalwood, jasmine, cascarilla, cocoa, licorice, and flavorings and flavor packages of the type and characteristics traditionally used in cigarette, cigar, and pipe tobacco flavorings. Syrups such as high fructose corn syrup may also be used. Flavoring agents may include acidic or basic characteristics (e.g., organic acids such as levulinic acid, succinic acid, and pyruvic acid). Representative types of aerosol precursor compositions are described in U.S. Pat. No. 4,793,365 (Sensabaugh, Jr. et al.), U.S. Pat. No. 5,101,839 (Jakob et al.), U.S. Patent Publication No. 2013 / 0008457 (Zheng et al.), and Chemical and Biological Studies on New Cigarette Prototypes that Heat Instead of Burn Tobacco, R.J. Reynolds Tobacco Company Monograph (1988). The disclosures of all of the foregoing documents are incorporated herein by reference in their entirety.
[0132] One or more acid components may be included in the aerosol precursor, for example, to modify the sensory characteristics of the aerosol precursor and the aerosol generated therefrom. Organic acids may be incorporated into the aerosol precursor to affect, inter alia, the taste, sensory, and / or organoleptic properties of nicotine. Such organic acids may be included in the aerosol precursor with variable amounts of nicotine ranging from more than equimolar to less than equimolar to nicotine (based on total organic acid content). A range of organic acids may be used, for example, according to embodiments as described in Perfetti, Beitrage Tabakforschung Int., 12, 43-54 (1983), which is incorporated herein by reference. Certain exemplary organic acids that may be useful include tartaric acid, ascorbic acid, fumaric acid, citric acid, malic acid, lactic acid, aspartic acid, salicylic acid, 4-aminosalicylic acid, N-acetyl-4-aminosalicylic acid, p-toluenesulfonic acid, succinic acid, pyruvic acid, formic acid, acetic acid, propionic acid, isobutyric acid, butyric acid, α-methylbutyric acid, 2-ketobutyric acid, isovaleric acid, β-methylvaleric acid, caproic acid, 2-furoic acid, phenylacetic acid, heptanoic acid, octanoic acid, nonanoic acid, oxalic acid, malonic acid, glycolic acid, levulinic acid, 4-aminobenzoic acid, 4-acetamidobenzoic acid, 3-hydroxybenzoic acid, 2,5- Examples of suitable organic acids include, but are not limited to, dihydroxybenzoic acid, 2,3-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, 3,4-dihydroxybenzoic acid, vanillic acid, mucic acid, cyclamic acid, benzenesulfonic acid, 2-hydroxyethanesulfonic acid, 1-hydroxy-2-naphthoic acid, ketoglutaric acid, D-glucuronic acid, maleic acid, glutamic acid, L-pyroglutamic acid, nicotinic acid, isonicotinic acid, gallic acid, phthalic acid, mandelic acid, hipuric acid, cinnamic acid, adipic acid, orotic acid, sorbic acid, clofibric acid, tauric acid, and combinations of two or more such organic acids. By using a nicotine salt, co-crystal, or salt co-crystal in place of nicotine, it may be possible in certain embodiments to reduce and / or eliminate the amount of acid advantageously incorporated into the aerosol precursor.
[0133] The amount of aerosol precursor composition used in a smoking article is such that the article exhibits acceptable sensory and organoleptic properties, as well as desirable performance characteristics. It is highly preferred that sufficient aerosol precursor composition components, such as, for example, glycerin and / or propylene glycol, are used to produce a visible mainstream aerosol that resembles the appearance of tobacco smoke in many respects. Typically, the amount of aerosol-generating material incorporated into a smoking article ranges from about 1.5 g or less, about 1 g or less, or about 0.5 g or less. The amount of aerosol precursor composition may depend on factors such as the number of puffs desired per cartridge used with the smoking article. It is desirable that the aerosol-generating composition does not introduce a significant degree of unacceptable bad taste, film-like mouth feel, or an overall sensory experience that is significantly different from that of traditional types of cigarettes that generate mainstream smoke by burning tobacco cut fillers. The selection of the specific aerosol-generating and reservoir materials, the amounts of those components used, as well as the type of tobacco material used, may be modified to control the overall chemical composition of the mainstream aerosol generated by the smoking article.
[0134] Typically, the amount of nicotine incorporated into the aerosol precursor of an electronic smoking article is sufficient to provide a desired amount of free nicotine in the aerosol generated therefrom.For example, the article can provide an amount of nicotine of about 0.01 mg to about 0.5 mg, about 0.05 mg to about 1 mg, about 0.08 mg to about 0.5 mg, about 0.1 mg to about 0.3 mg, or about 0.15 mg to about 0.25 mg per puff of the article.Thus, the amount of nicotine salt, co-crystal, or salt co-crystal incorporated into the aerosol precursor is, for example, sufficient to produce these amounts of nicotine when the article is used.
[0135] When the nicotine salts, cocrystals, or salt cocrystals described herein are used in electronic smoking articles, the temperature at which nicotine is released from the salt, cocrystal, or salt cocrystal into aerosol form is an important consideration. It is typically important that nicotine is released from the salt, cocrystal, or salt cocrystal (i.e., that nicotine is transferred to aerosol form) at the operating temperature of the electronic smoking article. Although not intended to be limiting, exemplary operating temperatures of electronic smoking articles are within the range of about 100°C to about 500°C (e.g., about 120°C to about 300°C). Thus, the selection of an appropriate nicotine salt, cocrystal, or salt cocrystal for incorporation into such products may depend, in part, on the characteristics of the bond between nicotine and the coformer and the volatility of the salt, cocrystal, or salt cocrystal. For example, nicotine citrate may not be a good salt for electronic smoking articles because it is not volatile enough.
[0136] Furthermore, in some embodiments, the temperature at which the coformer component(s) is released from the nicotine salt, co-crystal, or salt co-crystal may be a relevant consideration. It may be important to consider the temperature at which not only nicotine but also the nicotine salt, co-crystal, or salt co-crystal is transferred to the aerosol form, since it may not be advantageous for certain coformers (e.g., certain acids) to be present in the aerosol (and delivered to the user). In other embodiments, the coformer(s) of a given nicotine salt, co-crystal, or salt co-crystal may desirably be contained in the aerosol and desirably delivered to the user. In such cases, it may be advantageous to ensure that such coformer(s) are sufficiently volatile at the use temperature of the electronic smoking article. Additionally, any decomposition products generated via heating the nicotine salt, co-crystal, or salt co-crystal to the relevant temperature (i.e., the typical operating temperature of the electronic smoking article) should also be evaluated and considered during product preparation and selection for a particular application. Specifically, in certain embodiments, acid decomposition products produced via heating the nicotine salt, co-crystal, or salt co-crystal to the relevant temperatures should be evaluated and considered.
[0137] Thus, in certain embodiments, following preparation of the nicotine salts, co-crystals, or salt co-crystals described herein, they are analyzed to assess whether nicotine and / or coformers and / or their degradation products are transferred from the aerosol precursor to the aerosol. Such analysis may be performed, for example, by high performance liquid chromatography and / or gas chromatography of the aggregates collected from the aerosol. Both the presence and amount of nicotine and / or coformers and / or their degradation products are assessed to determine whether a given salt, co-crystal, or salt co-crystal is a good candidate for incorporation into an electronic smoking article.
[0138] In still further embodiments, the nicotine salts, cocrystals, and / or salt cocrystals disclosed herein may be incorporated into pharmaceutical products. For example, the nicotine salts, cocrystals, or salt cocrystals may be used as a replacement for or in addition to nicotine in nicotine-containing pharmaceutical products. Such products may be used to treat various conditions, diseases, and disorders that respond to the stimulation of one or more nicotinic acetylcholinergic receptors (nAChRs). These products may be used to treat those types of conditions, diseases, and disorders that have been reported to be treatable through the use or administration of nicotine as an agonist of nAChRs. As such, these products may be used to treat various CNS conditions, diseases, and disorders, and the compositions may also be used as smoking cessation aids (i.e., as a component of NRT). The combined amount of nicotine present (including nicotine present as salt, co-crystal, and / or salt co-crystal forms, and optionally one or more other forms of nicotine) is preferably an amount effective to treat some symptoms of the condition, disease, or disorder from which the subject or patient suffers, or to prevent their occurrence. Exemplary conditions, diseases, or disorders that can be treated include cognitive disorders such as Alzheimer's disease and attention deficit disorder, schizophrenia, Parkinson's disease, Tourette's syndrome, ulcerative colitis, dry eye disease, high blood pressure, depression, overactive bladder, obesity, lice / scabies, and bleeding. Such products can also find use as treatments to reduce stress or pain, and / or as smoking cessation aids.
[0139] The shape of the pharmaceutical product may resemble various pill, tablet, lozenge, capsule, caplet, pouch, and gum-type products traditionally used for administration of pharmaceutical types of products. The general nature of the representative compositions may be soft or hard feeling, medium softness or hardness, and as such, the compositions may be considered to be malleable, flexible, chewy, elastic, brittle, and the like. The pharmaceutical products containing the nicotine salts, cocrystals, or salt cocrystals provided herein are not limited to oral products, and compositions such as creams (including ointments, ointments, and pastes), liquids (e.g., sprays or enemas), and the like are also encompassed by the present invention. In addition, the nicotine salts, cocrystals, and salt cocrystals disclosed herein may also be incorporated into various delivery devices, such as inhalants (e.g., metered dose inhalants, dry powder inhalants, and sprays). Pharmaceutical products according to the invention can contain, in addition to the nicotine salts, co-crystals, and / or salt co-crystals described herein, one or more pharma- ceutically acceptable ingredients, such as excipients (e.g., salts, sweeteners, fillers, flavoring materials, anti-adherents, glidants, preservatives, and antioxidants, surfactants, dyes or pigments, lubricants, and / or processing aids).
[0140] The applications described focus on the incorporation of novel nicotine salts, co-crystals, and salt co-crystals. However, in some embodiments, known nicotine salts can be used in the compositions disclosed herein to provide novel compositions and / or novel products incorporating such compositions. For example, but not intended to be limiting, nicotine L-malate (CAS RN 253180-13-1), nicotine 4-acetamidobenzoic acid salt (CAS RN 110441-65-1), nicotine 3-hydroxybenzoic acid (CAS RN 1644394-41-1, e.g., as disclosed in International Application Publication No. 2015 / 006652), nicotine 2,5-dihydroxybenzoic acid (CAS RN 6012-21-1), nicotine 4-aminosalicylic acid salt (salt of 1-hydroxy-4-aminobenzoic acid) (CAS RN 20334-41-2), nicotine salicylic acid salt (salt of 2-hydroxybenzoic acid) (CAS RN 29790-52-1), nicotine phthalic acid salt (salt of 1,2-benzenedicarboxylic acid) (CAS RN Known salts such as nicotine N-acetyl-4-aminosalicylic acid (salt of N-acetyl-2-hydroxy-4-aminobenzoic acid) (CAS RN 900789-26-6), and / or nicotine di-L-(+)-tartaric acid dihydrate (CAS RN 6019-06-3) can be used in the compositions and products disclosed herein.
[0141] Although the described applications focus on the formation of nicotine salts, co-crystals, and salt co-crystals, and the incorporation of such formed nicotine salts, co-crystals, and salt co-crystals into various products, in some embodiments, it may be possible to form such nicotine salts, co-crystals, and salt co-crystals in situ. For example, nicotine may be complexed with one or more coformers, as broadly described herein, and optionally other ingredients (e.g., those types of ingredients typically contained in the product being formed), and the nicotine salt, co-crystal, or salt co-crystal is formed in situ. In other words, although often advantageous for reasons disclosed herein, isolation and / or purification of the nicotine salt, co-crystal, or salt co-crystal is not required in all embodiments prior to introduction into the product.
[0142] For example, in one embodiment, an aerosol precursor for an electronic smoking article can be prepared by mixing a nicotine salt, co-crystal, or salt co-crystal with the desired aerosol precursor components (e.g., carrier and flavorant), or by mixing nicotine, a coformer (e.g., acid), and the desired aerosol precursor components. See, for example, methods of incorporating certain salts into an aerosol device in International Application Publication No. WO 2014 / 182736 (Ploom, Inc.), which is incorporated herein by reference.
[0143] Aspects of the present invention will be more fully described by the following examples, which are set forth to illustrate certain specific aspects of the invention and are not to be construed as limiting thereof.
[0144] experiment common X-ray powder diffraction (XRPD) X-ray powder diffraction patterns are collected on a Bruker AXS C2 GADDS diffractometer using Cu Kα radiation (40 kV, 40 mA), an automated XYZ stage, a laser video microscope for automated sample positioning, and a HiStar 2D area detector. X-ray optics consist of a single Gobel multilayer mirror coupled with a 0.3 mm pinhole collimator. Weekly performance checks are performed using certified standard NIST 1976 corundum (flat plates). The beam divergence, i.e., the effective size of the X-ray beam on the sample, is approximately 4 mm. The θ-θ continuous scanning mode is used with a sample-detector distance of 20 cm, giving an effective 2θ range of 3.2° to 29.7°. Typically, the sample is exposed to the X-ray beam for 120 seconds. The software used for data collection is GADDS for XP / 2000 4.1.43, and Diffrac Plus EVA v13.0.0.2 or v15.0.0.0 is used to analyze and present the data.
[0145] Samples run under ambient conditions are prepared as powder flat specimens without polishing. Approximately 1-2 mg of sample is lightly pressed onto a glass slide to obtain a flat surface. Samples run under non-ambient conditions are mounted on a silicon wafer with a thermally conductive compound. The sample is heated to temperature at 20°C / min and then held isothermally for 1 min before starting data collection.
[0146] Single Crystal X-Ray Diffraction (SCXRD) Data are collected on a CCD diffractometer equipped with an Oxford Diffraction Supernova Dual Source, Cu at Zero, and an Atlas Oxford Cryosystems Cobra cooling device. Data are collected using CuKα radiation. Structures are typically solved using either the SHELXS or SHELXD programs, and refined using the SHELXL program as part of the Bruker AXS SHELXTL suite (V6.10). Unless otherwise stated, hydrogen atoms bonded to carbon atoms are geometrically placed, allowing them to be refined with mounted isotropic displacement parameters. Hydrogen atoms bonded to heteroatoms are positioned in a difference Fourier synthesis, allowing them to be freely refined with isotropic displacement parameters. EXAMPLES
[0147] Example 1. Salt of nicotine with mucic acid A screening experiment is first performed to evaluate a solvent-free method for the formation of salts of mucic acid. The required amount of mucic acid (for 100 μL of nicotine) is weighed into HPLC vials. (S)-nicotine is dispensed into each vial and the vials are rocked at room temperature for 3 days. The solids are sampled and characterized by XRPD. As shown in Table 1, the XRPD analysis results indicate that the solids formed in the vials contain a new crystalline phase morphology, indicating the formation of salts of mucic acid. [Table 1]
[0148] Because the slurry method for pure nicotine proved difficult to replicate on a large scale, various screening experiments were then conducted to evaluate alternative means for the preparation of the mucate salt of nicotine.
[0149] Experiments are performed to evaluate the preparation of mucate salts via slow evaporation from water. (S)-nicotine (100 μL) is dispensed into HPLC vials with enough mucic acid to make salts with 2:1, 1:1, and 1:2 ratios of nicotine:mucic acid. Water is added in 100 μL aliquots until a clear solution is obtained or after 2000 μL has been added. The 2:1 nicotine:mucic acid mixture produced a clear solution after the addition of 100 μL of water, but no solids were isolated. The 1:1 and 1:2 nicotine:mucic acid mixtures were poorly soluble in water and did not produce a clear solution even after the addition of 2000 μL of water, so these experiments were abandoned.
[0150] An experiment is performed to evaluate the preparation of mucate salts via anti-solvent mediated salt formation. One equivalent of mucic acid (to 100 μL of nicotine) is added to an HPLC vial and (S)-nicotine (100 μL) is dispensed into the vial. Ethanol is added in 1 mL portions until a clear solution is obtained or after 5 mL has been added. The mixture did not produce a clear solution even after the addition of 5 mL of ethanol, so this experiment was abandoned.
[0151] An experiment is performed to evaluate the preparation of a salt of mucate in tetrahydrofuran (THF). A saturated solution of mucic acid in THF is prepared and filtered prior to use. An aliquot of this stock solution (2 mL) is added to each of three separate HPLC vials and a given amount of (S)-nicotine is dispensed into each vial (25 μL, 50 μL, or 100 μL). The vials are rocked at room temperature for three days, after which all three vials contain a clear solution. The solution is cooled to 4° C. and allowed to evaporate for 24 hours. No solids are formed.
[0152] Additional attempts to prepare the mucate salt from ethanol / water and isopropyl alcohol / water systems also failed due to the poor solubility of the acid. Attempts to prepare the mucate salt from a DMSO / antisolvent system also failed to produce a solid mucate salt.
[0153] Thus, to produce nicotine mucate on a large scale, mucic acid (5.2 g, 25 mmol) is suspended in (S)-nicotine (10 mL) and stirred overnight at room temperature under argon. To the resulting gummy mixture, an additional 10 mL of nicotine is added and the mixture is stirred for an additional 60 hours. The solid that formed in the mixture was isolated by filtration, washed with cold THF and heptane, and dried. The solid was further slurried in ethyl acetate for 50 hours at room temperature, isolated by filtration, washed with ethyl acetate and heptane, and dried to give a pink solid (7.21 g, 94.2% yield).
[0154] The solids were analyzed by a variety of techniques, including XRPD, and the pattern is shown in Figure 1. A representative peak list for the XPRD of nicotine mucate is provided in Table 2. [Table 2] TIFF2024156667000003.tif194161
[0155] The sample is shown in FIG. 1 Further analysis by methods including H NMR (solid shows to consist of 0.72 equivalents of acid, true stoichiometry of this form unknown); PLM (shows irregular birefringent particles, typically less than 10 μm); TGA (shows 91% mass loss from 25-260 °C in multiple unresolved steps); DSC (shows a sharp endotherm at 123 °C (73 J / g) and a broad endotherm at 133 °C (27 J / g)); and GVS (shows 60% water uptake from 0-90% RH, although equilibrium was not reached at 90% RH so the actual water uptake may be higher). The solid is rather hygroscopic.
[0156] Example 2.4 - Salt of Nicotine with Acetamidobenzoic Acid A screening experiment is first performed to evaluate a solvent-free method for the formation of salts of 4-acetamidobenzoic acid. 4-Acetamidobenzoic acid (111 mg) is suspended in the minimum amount of (S)-nicotine required to produce a mobile slurry (400 μL). The slurry is rocked at room temperature for 48 hours. The resulting white powder solid is isolated by filtration, sampled and characterized by XRPD, showing a new crystalline morphology.
[0157] Because the slurry method for pure nicotine proved difficult to replicate on a large scale, a screen was next performed to evaluate alternative means for the preparation of the 4-acetamidobenzoate salt of nicotine.
[0158] An experiment is performed to evaluate a solvent-free method for the formation of salts of 4-acetamidobenzoic acid. 4-acetamidobenzoic acid is dissolved in a minimum amount of THF (400 μL) and (S)-nicotine (1 equivalent) is added. The solution is covered and left at room temperature overnight, then at 4° C. for 24 hours, and at −18° C. for 24 hours. Very little solid was present in the mixture at each time point. The cover is removed and the solvent is allowed to evaporate to give a crystalline solid. The solid is sampled and characterized as a crystalline solid by XRPD, the results of which are consistent with those calculated based on the single crystal structure of the salt of nicotine 4-acetamidobenzoate (see FIG. 3).
[0159] On a larger scale, 4-acetamidobenzoic acid (5.55 g, 31 mmol) is dissolved in THF (280 mL) at room temperature. The slightly cloudy solution is passed through a 0.45 μm PTFE filter, then (S)-nicotine (5 mL, 31 mmol) is added in 1 mL portions. The resulting clear solution is stirred at room temperature for 10 min and then concentrated to approximately one-third of its original volume. The solution is seeded with 2 mg of previously prepared nicotine 4-acetamidobenzoate to induce rapid crystallization. The mixture is shaken at room temperature for 5 min and allowed to stand for 1 h. The solid is isolated by filtration, washed with ethyl acetate and heptane, and dried to give 5.42 g of a white solid (51% yield).
[0160] The solid was analyzed by XRPD and the pattern is shown in Figure 3, which compares the experimental XRPD data obtained at room temperature with the XRPD pattern calculated from single crystal X-ray data at 100 K. A representative peak list for the (experimental) XPRD of nicotine 4-acetamidobenzoate is provided in Table 3. [Table 3] TIFF2024156667000005.tif148165
[0161] 1 The solid is further analyzed by a variety of techniques, including H NMR (indicating the solid consists of 1.04 equivalents of acid); PLM (showing irregular birefringent laths up to 75 μm long); TGA (showing 64% mass loss from 25-360 °C in two unresolved steps); DSC (showing a sharp endotherm at 134 °C (151 J / g) and a broad endotherm at 143 °C (43 J / g)); and GVS (showing water uptake of 5% from 0-80% RH and 20% from 80-90% RH). XRPD analysis followed by GVS indicates the solid is unchanged.
[0162] The resulting crystal structures for two independent molecules of nicotine 4-acetamidobenzoate are shown in Figures 4A and 4B. The resulting crystal packing of nicotine 4-acetamidobenzoate is provided in Figure 4C, with the nicotine molecules shown in grey and the acid molecules in black.
[0163] The crystallographic parameters of the isolated form are provided in Table 4. The structure solution was obtained by the direct method, F 2 By full matrix least-squares refinement on -1 = σ 2 (F o 2 )+(0.0575P) 2 +(1.5000P), P=(F o 2 +2F C 2) / 3, anisotropic displacement parameters were used. Experimental absorption corrections using spherical harmonics were implemented in the SCALE3 ABSPACK scaling algorithm. Absolute structure parameter = 0.04(16) (also known as the Flack parameter, which should be near zero for the correct absolute stoichiometry and near agreement for the transformed absolute structure (standard uncertainty). Cf. Flack HD (1983), Acta Cryst. A39, 876-881). The SCXRD structure provided confirmation that nicotine has an S absolute stoichiometry. For all data, the final wR 2 ={Σ[w(F o 2 -F C 2 ) 2 ] / Σ[w(F o 2 ) 2 ] 1 / 2}=0.0976, and for the F value of 6624 refractive index, the conventional R 1 =0.0356, F o >4σ(F o ) for all data and 471 parameters, S = 1.001. Final Δ / σ(max) 0.000, Δ / σ(average) 0.000. +0.193~-0.207eÅ -3 Final difference map. [Table 4]
[0164] Example 3. Salt of nicotine with gentisinic (2,5-hydroxybenzoic) acid A screening experiment is first performed to evaluate a solvent-free method for the formation of salts of gentisic acid. Gentisic acid (95 mg) is suspended in the minimum amount of (S)-nicotine required to produce a mobile slurry (200 μL). The slurry is rocked at room temperature for 48 hours. The resulting pink solid is isolated by filtration, sampled and characterized by XRPD, showing a new crystalline form.
[0165] An experiment is performed to evaluate a solvent-free method for the formation of salts of gentisic acid. Gentisic acid is dissolved in a minimum amount of THF (200 μL) and (S)-nicotine (1 equivalent) is added. The solution is covered and left at room temperature overnight, then at 4° C. for 24 hours, and at −18° C. for 24 hours. At each time point, a clear solution was present in the mixture. The cover was removed and the solvent was allowed to evaporate, but this did not result in an isolated solid.
[0166] On a larger scale, gentisic acid (4.75 g, 31 mmol) is dissolved in THF (50 mL) at room temperature. (S)-nicotine (5 mL, 31 mmol) is added in 1 mL portions and the resulting clear solution is stirred at room temperature for 10 min. The solution is seeded with 2 mg of previously prepared nicotine gentisate salt, rapid crystallization occurs and the mixture is stirred at room temperature for 10 min. The solid is isolated by filtration, washed with THF and heptane and dried to give 7.20 g of a white solid (74% yield).
[0167] The solid was analyzed by XRPD and the pattern is shown in Figure 5, which compares the experimental XRPD data obtained at room temperature with the XRPD pattern calculated from single crystal X-ray data at 100 K. A representative peak list for the (experimental) XPRD of nicotine gentisate is provided in Table 5. [Table 5] TIFF2024156667000008.tif234159TIFF2024156667000009.tif44157
[0168] 1The solid is further analyzed by a variety of techniques including H NMR (indicating the solid consists of 1.00 equivalents of acid); PLM (showing irregular birefringent laths up to 100 μm long); TGA (showing 95% mass loss from 25-280 °C); DSC (showing a sharp endotherm at 149 °C (102 J / g)); as well as GVS (showing 0.3% water uptake from 0-90% RH). XRPD analysis followed by GVS shows the solid is unchanged. The salt of gentisic acid compares well with commercially available nicotine ditartrate in terms of thermal stability.
[0169] The resulting crystal structure of a molecule of nicotine gentisate is shown in Figure 6 A. The resulting crystal packing of nicotine gentisate is provided in Figure 6 B, with nicotine molecules shown in grey and acid molecules in black.
[0170] The crystallographic parameters of the isolated form are provided below in Table 6. The structure solution was obtained by the direct method, F 2 By full matrix least-squares refinement on -1 = σ 2(F o 2 )+(0.0720P) 2 +(0.0060P), P=(F o 2 +2F C 2 ) / 3, anisotropic displacement parameters. Experimental absorption corrections using spherical harmonics were implemented in the SCALE3 ABSPACK scaling algorithm. Absolute structure parameter = 0.4(3). For all data, the final wR 2 ={Σ[w(F o 2 -F C 2 ) 2 ] / Σ[w(F o 2 ) 2 ] 1 / 2}=0.1342, and for the F value of the 2025 refraction, the conventional R 1 =0.0472, F o >4s(F o) for all data and 221 parameters, S = 1.004. Final D / s (max) 0.000, D / s (average) 0.000. +0.173~-0.219eÅ -3 Final difference map.
[0171] Because the collected data was not suitable for determining the absolute configuration, the stoichiometry of the nicotine moiety was fixed by the input materials and by the structure determined in Example 2 (i.e., having the S enantiomer of nicotine). [Table 6]
[0172] Example 4. Salts of nicotine with 3-hydroxybenzoic acid A screening experiment is first performed to evaluate a solvent-free method for the formation of salts of 3-hydroxybenzoic acid. 3-Hydroxybenzoic acid (85 mg) is suspended in the minimum amount of (S)-nicotine required to produce a mobile slurry (200 μL). The slurry is rocked at room temperature for 48 hours. The resulting gum is sampled and characterized by XRPD (indicating that the sample is dissolved).
[0173] On a larger scale, 3-hydroxybenzoic acid (4.25 g, 31 mmol) is dissolved in THF (50 mL) at room temperature by stirring for 10 min. (S)-nicotine (5 mL, 31 mmol) is added in 1 mL portions with constant stirring, and the resulting clear solution is stirred at room temperature for 10 min. The solution is seeded with 2 mg of previously prepared nicotine 3-hydroxybenzoate, causing rapid crystallization, and the mixture is stirred at room temperature for 1 min. The solid is isolated by filtration, washed with cold THF and heptane, and dried to give 4.81 g of a white solid (52% yield).
[0174] The solids were analyzed by XRPD and the pattern is shown in Figure 7. A representative peak list for the XPRD of nicotine 3-hydroxybenzoate is provided in Table 7. [Table 7] TIFF2024156667000012.tif149154
[0175] 1 The solid is further analyzed by a variety of techniques including H NMR (indicating the solid consists of 1.03 equivalents of acid); PLM (indicating irregular sharp-edged particles); TGA (indicating 89% mass loss from 25-360 °C in two unresolved steps); DSC (indicating a sharp endotherm at 123 °C (131 J / g)); and GVS (indicating water uptake of 0.5% from 0-80% RH and 5% from 80-90% RH). XRPD analysis followed by GVS indicates the solid is unchanged.
[0176] Example 5. Salt of Nicotine with L-Malic Acid A screening experiment is first performed to evaluate a solvent-free method for the formation of salts of L-malic acid. The required amount of L-malic acid (for 100 μL of nicotine) is weighed into HPLC vials at ratios of 2:1, 1:1, and 1:2 nicotine:acid. (S)-nicotine is dispensed into each vial and the vials are rocked at room temperature for 3 days. The solids are sampled and characterized by XRPD.
[0177] An experiment is performed to evaluate the preparation of salts of L-malic acid via slow evaporation from water. (S)-nicotine (100 μL) is dispensed into an HPLC vial along with enough mucic acid to make salts with 2:1, 1:1, and 1:2 ratios of nicotine:L-malic acid. Water is added in 100 μL aliquots until a clear solution is obtained or after 2000 μL has been added. All mixtures of nicotine and L-malic acid produced clear solutions after the addition of 200 μL of water, but no solids were isolated.
[0178] An experiment is performed to evaluate the preparation of salts of L-malate via anti-solvent mediated salt formation. One equivalent of L-malic acid (for 100 μL of nicotine) is added to an HPLC vial and (S)-nicotine (100 μL) is dispensed into the vial. Ethanol is added in 1 mL portions until a clear solution is obtained or after 5 mL has been added. After the addition of 2000 μL of ethanol, a clear solution was obtained. EtOAc was then added in 1 mL portions until persistent suspension was observed or 10 mL had been added. After the addition of 3000 μL, the material was observed to oil. The mixture was placed at 4° C. overnight after which a viscous gum was observed. The mixture was then placed at −18° C. for one week after which a viscous gum was observed. The gum was placed in an incubator and aged at ambient temperature to 50° C. for a period of one week at 8 hour intervals after which the mixture appeared to be a viscous solution.
[0179] An experiment was conducted to evaluate the preparation of L-malate salt by freeze-drying and subsequent aging. A stock solution is prepared by complexing (S)-nicotine (120 μL) with one equivalent of acid in water (12 mL). The solution is shaken at room temperature to obtain a clear homogenous phase. A portion of the relevant stock solution (1 mL) is dispensed into each of 10 vials, which are frozen and lyophilized overnight to remove the water. An aliquot of aging solvent (100 μL of acetone, EtOH, IPA, toluene, dioxane, IPAc, TBME, acetone + 5% water, EtOH + 5% water, IPA + 5% water) is added to each vial and the vials are shaken at room temperature for 4 days. The vial containing IPA yielded a solid malate salt as determined by XRPD. The vials containing IPAc and TBME were observed to contain oil / gum and all other vials were observed to contain clear solutions.
[0180] To prepare nicotine L-malate on a large scale, malic acid (2.84 g, 21 mmol) is dissolved in THF (30 mL) by stirring at room temperature for 10 min. (S)-nicotine (5.0 mL, 31 mmol) is added, causing immediate precipitation of a white solid. The slurry is seeded with 2 mg of previously prepared nicotine L-malate and stirred at room temperature overnight. The solid formed in the mixture is isolated by filtration, washed with cold THF and heptane, and dried to give a white solid (5.78 g, 92% yield).
[0181] The solids were analyzed by XRPD and the pattern is shown in Figure 8. A representative peak list for the XPRD of nicotine L-malate is provided in Table 8. [Table 8] TIFF2024156667000014.tif195165
[0182] 1 The solid is further analyzed by a variety of techniques including H NMR (indicating the solid consists of 1.07 equivalents of acid); PLM (indicating irregular birefringent particles typically smaller than 25 μm); TGA (indicating 91% mass loss from 25-260°C); DSC (indicating a small endotherm at 107°C (1 J / g), a sharp endotherm at 120°C (120 J / g), and a broad endotherm at 168°C (452 J / g)); and GVS (indicating 70% water uptake from 0-90% RH, although the actual water uptake may actually be higher since equilibrium was not reached at 90% RH). The small endotherm may be possible evidence of the presence of a second polymorph. XRPD analysis followed by GVS indicates that the solid has dissolved.
[0183] Example 6. Salt of nicotine with 3,5-dihydroxybenzoic acid A screening experiment is first performed to evaluate the formation of a nicotine salt with 3,5-dihydroxybenzoic acid by crystallization from pure nicotine. 3,5-dihydroxybenzoic acid (25 mg) is complexed with (S)-nicotine (100 μL) and the mixture is stirred overnight at room temperature. 3,5-dihydroxybenzoic acid dissolves in nicotine and no solids are observed.
[0184] An experiment is performed to evaluate the preparation of salts of 3,5-dihydroxybenzoic acid via crystallization from THF. 3,5-dihydroxybenzoic acid (approximately 40 mg) is dispensed into a vial and THF is added in portions, vortexing briefly after each addition. The addition was stopped when 10 portions had been added as a clear solution was obtained. (S)-nicotine (1 molar equivalent) is then added to the vial and the vial is rocked overnight at room temperature. The resulting mixture is a clear solution and no solids are isolated.
[0185] An experiment is performed to evaluate the preparation of salts of 3,5-dihydroxybenzoic acid via crystallization from water. 3,5-dihydroxybenzoic acid (approximately 50 mg) is dispensed into a vial and water is added in portions, stirring at 80° C. for 10 minutes after each addition. The addition was stopped when 3 portions had been added as a clear solution was obtained. (S)-nicotine (1 molar equivalent, 52.6 mg) is then added to the vial and the vial is left at room temperature overnight. After 24 hours the mixture is still a clear solution and placed at 5° C., but no solids are observed after evaporation of the liquid.
[0186] An experiment is performed to evaluate the preparation of salts of 3,5-dihydroxybenzoic acid via crystallization from ethanol. 3,5-dihydroxybenzoic acid (approximately 50 mg) is dispensed into a vial and ethanol is added in portions, stirring at 70° C. for 10 minutes after each addition. The addition is stopped when 3 portions have been added, as a clear solution is obtained. (S)-nicotine (1 molar equivalent, 52.6 mg) is then added to the vial and the vial is left at room temperature overnight. After 24 hours, the mixture is still a clear solution and placed at 5° C., but no solids are observed after evaporation of the liquid.
[0187] An experiment is performed to evaluate the preparation of salts of 3,5-dihydroxybenzoic acid via crystallization from acetone. 3,5-dihydroxybenzoic acid (approximately 50 mg) is dispensed into a vial and acetone is added in portions, stirring at 50° C. for 10 minutes after each addition. The addition is stopped when 10 portions have been added as a clear solution is obtained. (S)-nicotine (1 molar equivalent, 52.6 mg) is then added to the vial and the vial is left at room temperature overnight. Following evaporation, a solid formed in the vial at room temperature, but attempts to characterize the solid by XPRD were unsuccessful as the solid became a gum. This preparation from acetone is repeated to explore aging as a method to induce crystallization by mixing 50 mg of 3,5-dihydroxybenzoic acid, 10 portions of acetone, and 1 equivalent of nicotine in a vial. The resulting mixture is cycled at room temperature to 50° C. for 8 hour intervals over a period of 2 weeks. A solid was obtained and analyzed by XPRD (showing a new morphology) and 1 The material was analyzed by H NMR (showing a 1:1 salt). The resulting crystals were analyzed further to allow for the collection of an SCXRD structure (showing that the material is an anhydrous salt). The crystal structure is provided in Figure 13.
[0188] On a larger scale, 3,5-dihydroxybenzoic acid (5.66 g) is dissolved in THF (56 mL) at 50 °C. (S)-nicotine (5.9 mL, 1 equiv.) is added, followed by seeding with previously prepared nicotine 3,5-dihydroxybenzoate (~1 mg). After cooling to 25 °C and stirring for ~16 h, the solid is isolated by filtration, washed with heptane (2 x 2 mL), and dried under vacuum at room temperature for ~16 h to give 7.55 g (65% yield) of a white solid. The dihydrate form (nicotine 3,5-dihydroxybenzoate dihydrate) is prepared by placing anhydrous nicotine 3,5-dihydroxybenzoate (100 mg) in an open glass vial and exposing nicotine 3,5-dihydroxybenzoate to an atmosphere of 96% RH at 25 °C for 16 h. A sample of this is removed from the vial and characterized by XRPD to confirm that the dihydrate form was obtained.
[0189] The change in salt form of anhydrous 3,5-dihydroxybenzoate upon exposure to different humidity levels is an indication of the ability of this salt to exist in one or more hydrated forms. GVS experiments seem to show conversion to monohydrate and dihydrate forms, as well as suggesting the presence of another anhydrous form (GVS water uptake of 10% from 0-90% RH for the anhydrous form). VH-XRPD experiments confirmed the presence of the dihydrate (exhibiting the same XRPD diffractogram as material resulting from storage of Form 1 at 25°C / 96% RH), but it was not possible to observe the putative monohydrate and alternative anhydrous forms. The dihydrate was subsequently prepared by exposure of the anhydrous form to humidity (at 40°C and 75% relative humidity, and converted during storage at 25°C and 96% relative humidity). Thermal analysis of this (converted) form indicates that it can reconvert to the known anhydrous form upon heating. No events that could be considered to represent a phase transition were observed in the DSC thermograms for either salt, the only event being apparent dissolution: specifically, the anhydrous form exhibited a dissolution onset at 138°C, and the dihydrate form exhibited an endotherm between 50-100°C and a dissolution onset at 137°C.
[0190] The anhydrous form was further analyzed by PLM (which typically shows irregular particles below 10 μm) and the anhydrous and dihydrate forms were 1 Analyzed by H NMR (showing 1:1 stoichiometry for both forms). Single crystal X-ray diffraction studies were performed on anhydrous nicotine 3,5-dihydroxybenzoate and the structure was solved as shown in the ellipse plot in Figure 13 (this is the form made during small scale screening studies, which is a different form than that obtained during large scale production). A plot showing hydrogen bonding in the asymmetric unit of anhydrous nicotine 3,5-dihydroxybenzoate is shown in Figure 14A and a plot showing crystal packing for this salt is provided in Figure 14B.
[0191] Both solids (anhydrous and dihydrate forms) were analyzed by XRPD and the patterns are shown in Figures 9 and 11, respectively. A representative peak list for the XRPD of anhydrous nicotine 3,5-dihydroxybenzoate is provided in Table 9, and a representative peak list for the XRPD of nicotine 3,5-dihydroxybenzoate dihydrate is provided in Table 10. [Table 9] TIFF2024156667000016.tif135155 [Table 10] TIFF2024156667000018.tif240161TIFF2024156667000019.tif36158
[0192] Nicotine 3,5-dihydroxybenzoate in anhydrous and dihydrate forms, 1 The salts are further analyzed by various techniques, including H NMR, as shown in Figures 10 and 12, respectively. Note that in both of these NMR spectra the broad resonance at about 9.6 ppm is believed to arise from the COOH acidic protons and reflects their environment in the DMSO solutions analyzed, which is not necessarily the same as in the solid state. In the solid state, as proton transfer occurs, the proton is expected to be on the nitrogen atom of nicotine, whereas in DMSO solution, the salt is understood to be in equilibrium with the dissociated species.
[0193] The crystallographic parameters of the isolated form are provided below in Table 11. The structure solution was obtained by the direct method, F 2 By full matrix least-squares refinement on w -1 =1 / [σ 2 (F o 2 )+(0.0659P) 2 +0.2704P], P=(F o 2 +2F c 2) / 3, anisotropic displacement parameters were used. Semi-empirical attenuation correction using direct methods was implemented in SHELXTL. Absolute structural parameters = 0.02(7). For all data, the final wR 2 = 0.0992, and the F value of the 6431 refraction is the same as the conventional R 1 =0.0383, F o >4s(F o ) and for all data, S=1.050. +0.186~-0.224eÅ -3 Final difference map. [Table 11]
[0194] Example 7. Salt of nicotine with 2,3-dihydroxybenzoic acid A screening experiment is first performed to evaluate the formation of a nicotine salt with 2,3-dihydroxybenzoic acid by crystallization from pure nicotine. 2,3-dihydroxybenzoic acid (approximately 25 mg) is complexed with (S)-nicotine (100 μL) and the mixture is shaken at room temperature overnight. The resulting solid material is sampled and characterized by XPRD (showing a new morphology). The study is repeated on a 100 mg scale and the resulting solid is isolated by filtration, washed with heptane (2 × 1 mL) and analyzed by XPRD and 1 Characterized by 1 H NMR (showed 1:1 stoichiometry).
[0195] An experiment is performed to evaluate the preparation of salts of 2,3-dihydroxybenzoic acid via crystallization from THF. 2,3-dihydroxybenzoic acid (approximately 40 mg) is dispensed into a vial and THF is added in portions, vortexing briefly after each addition. The addition is stopped when 10 portions have been added, as a clear solution is obtained. (S)-nicotine (1 molar equivalent) is then added to the vial and the vial is rocked overnight at room temperature. The resulting mixture is a clear solution and no solids are observed.
[0196] An experiment is performed to evaluate the preparation of salts of 2,3-dihydroxybenzoic acid via crystallization from water. 2,3-dihydroxybenzoic acid (approximately 50 mg) is dispensed into a vial and water is added in portions, stirring at 80° C. for 10 minutes after each addition. The addition is stopped when 20 portions have been added, as a clear solution is obtained. (S)-nicotine (1 molar equivalent, 52.6 mg) is then added to the vial and the vial is left at room temperature overnight. After 24 hours, the mixture is still a clear solution and placed at 5° C., but no solids are observed after evaporation of the liquid.
[0197] An experiment is performed to evaluate the preparation of salts of 2,3-dihydroxybenzoic acid via crystallization from ethanol. 2,3-dihydroxybenzoic acid (approximately 50 mg) is dispensed into a vial and ethanol is added in portions, stirring at 70° C. for 10 minutes after each addition. The addition is stopped when 10 portions have been added, as a clear solution is obtained. (S)-nicotine (1 molar equivalent, 52.6 mg) is then added to the vial and the vial is left at room temperature overnight. After 24 hours, the mixture is still a clear solution and placed at 5° C., but no solids are observed after evaporation of the liquid.
[0198] An experiment is performed to evaluate the preparation of salts of 2,3-dihydroxybenzoic acid via crystallization from acetone. 2,3-dihydroxybenzoic acid (approximately 50 mg) is dispensed into a vial and acetone is added in portions, stirring at 50° C. for 10 minutes after each addition. The addition is stopped when 10 portions have been added, as a clear solution is obtained. (S)-nicotine (1 molar equivalent, 52.6 mg) is then added to the vial and the vial is left at room temperature overnight. No solids are observed and the solvent is allowed to evaporate, but no solids are observed even after evaporation.
[0199] To prepare nicotine 2,3-dihydroxybenzoate on a large scale, 2,3-dihydroxybenzoic acid (4.47 g) is dissolved in THF (8.9 mL) at room temperature. Although not successful on a small scale (as above), (S)-nicotine (4.7 mL) is added, causing immediate precipitation of a crystalline solid. The slurry is diluted with additional THF (3 mL) and stirred at room temperature for 1 h. The solid present is isolated by filtration, washed with heptane (2×3 mL), and dried under vacuum at room temperature for 60 h to give an off-white solid (7.90 g, 86% yield). Without intending to be limiting, the failure of the small scale salt crystallization attempt from THF (large scale salt preparation from THF was successful) is believed to be due to the dilution effect. The small scale crystallization attempt was performed using an excess of THF, and it is believed that under such conditions the solid remained dissolved and no precipitation was observed due to the presence of this excess THF. However, less THF was used relative to the 2,3-dihydroxybenzoic acid in the large scale process to form a solid.
[0200] The solids were analyzed by XRPD and the pattern is shown in Figure 12. A representative peak list for the XPRD of nicotine 2,3-dihydroxybenzoate is provided in Table 12. [Table 12] TIFF2024156667000022.tif235161TIFF2024156667000023.tif49162
[0201] Nicotine 2,3-dihydroxybenzoate, 1 Further analysis by various techniques including H NMR (indicating the salt has a 1:1 stoichiometry); PLM (indicating irregular plates up to about 150 μm); TGA (indicating a two-stage mass loss from 150 °C); DSC (indicating dissolution occurs at 157 °C), as well as GVS (indicating water uptake of 0.12% from 0-90% RH).
[0202] Example 8. Salt of nicotine with 1-hydroxy-2-naphthoic acid A screening experiment is first performed to evaluate the formation of nicotine salt with 2,3-dihydroxybenzoic acid by crystallization from pure nicotine. 1-Hydroxy-2-naphthoic acid (approximately 25 mg) is complexed with (S)-nicotine (100 μL) and the mixture is stirred at room temperature overnight. The resulting solid material is sampled and characterized by XPRD (showing a new morphology). The study is repeated on a 100 mg scale and the resulting solid is isolated by filtration, washed with heptane (2 × 1 mL) and analyzed by XPRD and 1 Characterized by 1 H NMR (showed 1:1 stoichiometry).
[0203] An experiment is performed to evaluate the preparation of salts of 1-hydroxy-2-naphthoic acid via crystallization from THF. 1-Hydroxy-2-naphthoic acid (approximately 40 mg) is dispensed into a vial and THF is added in portions, vortexing briefly after each addition. The addition is stopped when 10 portions have been added, as a clear solution is obtained. (S)-nicotine (1 molar equivalent) is then added to the vial, and the vial is rocked overnight at room temperature. The resulting mixture is a clear solution, which after precipitation gives a solid salt (which gives the same XPRD pattern as that obtained by preparation in pure nicotine).
[0204] An experiment is performed to evaluate the preparation of salts of 1-hydroxy-2-naphthoic acid via crystallization from water. 1-Hydroxy-2-naphthoic acid (approximately 50 mg) is dispensed into a vial and water is added in portions, stirring at 80° C. for 10 minutes after each addition. A solution of the acid in water was never obtained (after adding 20 portions of water). (S)-Nicotine (1 molar equivalent) was added and the slurry was stirred at 80° C. overnight. No change in the XRPD pattern compared to the acid was observed, indicating no formation of the salt form.
[0205] An experiment is performed to evaluate the preparation of 1-hydroxy-2-naphthoic acid via crystallization from ethanol. 1-Hydroxy-2-naphthoic acid (approximately 50 mg) is dispensed into a vial and water is added in portions, stirring at 70° C. for 10 minutes after each addition. The addition is stopped when 10 portions have been added as a clear solution is obtained. (S)-nicotine (1 molar equivalent, 52.6 mg) is then added to the vial and the vial is left at room temperature overnight. It formed at room temperature in the vial but attempts to characterize the solid by XPRD were unsuccessful as the solid became a gum. This preparation from ethanol was repeated and aging was explored as a method to induce crystallization by mixing 50 mg of 1-hydroxy-2-naphthoic acid, 10 portions of ethanol, and 1 equivalent of nicotine in a vial. The resulting mixture was cycled at room temperature to 50° C. for 8 hour intervals over a period of 2 weeks. Only clear solutions were obtained.
[0206] An experiment is performed to evaluate the preparation of 1-hydroxy-2-naphthoic acid salt via crystallization from acetone. 1-Hydroxy-2-naphthoic acid (approximately 50 mg) is dispensed into a vial and acetone is added in portions, stirring at 50° C. for 10 minutes after each addition. The addition is stopped when 10 portions have been added, as a clear solution is obtained. (S)-nicotine (1 molar equivalent, 52.6 mg) is then added to the vial and the vial is left at room temperature overnight. No solids were observed and the solvent was evaporated, but no solids were isolated even after evaporation.
[0207] To prepare nicotine 1-hydroxy-2-naphthoate on a large scale, 1-hydroxy-2-naphthoic acid (5.02 g) is dissolved in THF (10.0 mL) at room temperature. (S)-nicotine (4.3 mL) is added, followed by seeding with the desired salt form (approximately 1 mg), causing immediate precipitation of a crystalline solid. The slurry is stirred at room temperature for 30 min, and the solids present are isolated by filtration, washed with heptane (2 x 2 mL), and dried under vacuum at room temperature for 16 h to give an off-white solid (6.49 g, 69% yield).
[0208] The solids were analyzed by XRPD and the pattern is shown in Figure 17. A representative peak list for the XPRD of nicotine 1-hydroxy-2-naphthoate is provided in Table 13. [Table 13] TIFF2024156667000025.tif234158TIFF2024156667000026.tif21161
[0209] The solid nicotine 1-hydroxy-2-naphthoate is 1 Further analysis by various techniques including H NMR (indicating the salt has a 1:1 stoichiometry); PLM (indicating irregular particles up to about 100 μm); TGA (indicating a two-stage mass loss from 130 °C); DSC (indicating dissolution occurs at 111 °C), as well as GVS (indicating a water uptake of 0.16% from 0-90% RH).
[0210] Example 9. Thermal Decomposition Studies Several salts of nicotine, including nicotine mucate, nicotine 4-acetamidobenzoate, nicotine gentisate, nicotine 3-hydroxybenzoate, nicotine L-malate, nicotine 3,5-dihydroxybenzoate, nicotine 2,3-dihydroxybenzoate, and nicotine 1-hydroxy-2-naphthoate, are pyrolyzed in helium at 650°C to evaluate the pyrolysis products produced from each salt upon heating. All samples produce high yields of nicotine, indicating that nicotine is liberated from the salts at the temperatures evaluated.
[0211] The instrument used in the experiments was a filament pyrolyzer device aligned with a GC / MS instrument. During the pyrolysis process, compounds typically released (in addition to nicotine) were the decarboxylated molecules corresponding to the analyzed acids, free carbon dioxide, and water. For most salts, no decomposition of nicotine was observed.
[0212] Example 10. Salt-containing lozenges Several salts of nicotine, including nicotine mucate, nicotine salicylate, nicotine 4-acetamidobenzoate, nicotine gentisate, nicotine 3-hydroxybenzoate, nicotine L-malate, nicotine 3,5-dihydroxybenzoate, nicotine 2,3-dihydroxybenzoate, and nicotine 1-hydroxy-2-naphthoate, are incorporated into smokeless tobacco products in the form of lozenges. The lozenges may generally include ingredients disclosed in US Patent Application Publication No. 2013 / 0078307 (Holton, Jr.), which is incorporated herein by reference. For example, a representative lozenge may include isomalt, maltitol syrup, flavoring material(s), water, and a nicotine compound (with one or more of the nicotine salts, co-crystals, or salt co-crystals disclosed herein used in place of the nicotine compounds disclosed in the references). The amount of nicotine salt, co-crystal, or salt co-crystal included in each lozenge is sufficient to provide 2 mg of nicotine (adjusted based on the weight of the particular coformer). The sensory (e.g., taste and mouth feel) characteristics and / or stability of the lozenge can be influenced in some embodiments by the selection of the nicotine salt, co-crystal, or salt co-crystal.
[0213] In some embodiments, one or more ingredients are typically incorporated into nicotine-containing lozenges to prevent volatilization of the nicotine therein (including, but not limited to, citric acid), and since providing nicotine in this form may itself prevent volatilization of the nicotine, the nicotine salts, co-crystals, and salt co-crystals disclosed herein may, in some embodiments, be incorporated into the lozenges without such ingredients.
[0214] Numerous modifications and other embodiments of the invention will come to mind to one skilled in the art to which this invention pertains having the benefit of the teachings presented in the foregoing description. It is to be understood, therefore, that the invention is not limited to the specific embodiments disclosed, and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.
Claims
1. Salts of nicotine and mucic acid; salts of nicotine and 3,5-dihydroxybenzoic acid; salts of nicotine and 2,3-dihydroxybenzoic acid; crystalline polymorphic forms of nicotine 1-hydroxy-2-naphthoate, said forms being characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2θ diffraction angles: 15.6, 16.1, 20.5, 22.5, and 27.1; crystalline polymorphic forms of nicotine 4-acetamidobenzoate, said forms being characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2θ diffraction angles: 15.6, 16.1, 20.5, 22.5, and 27.1; and a crystalline polymorphic form of nicotine gentisate, said form being characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 16.839, 17.854, 20.134, and 23.265; and a crystalline polymorphic form of nicotine gentisate, said form being characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 13.000, 19.017, 20.194, and 21.
000.
2. 2. The nicotine salt or crystalline polymorphic form of claim 1, comprising a salt of nicotine and mucic acid, said form being characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2θ diffraction angles: 14.289, 15,449, 19.66, and 20.
412.
3. 2. The nicotine salt or crystalline polymorphic form of claim 1, wherein at least about 50% of the salt or crystalline polymorphic form is in crystalline form.
4. 2. The nicotine salt or crystalline polymorphic form of claim 1, comprising a salt of nicotine and 3,5-dihydroxybenzoic acid, said form being an anhydrous form characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2θ diffraction angles: 12.7, 17.8, 19.7, 20.2, 21.3, 24.5, 24.9, 25.8, and 29.
8.
5. 2. The nicotine salt or crystalline polymorphic form of claim 1, comprising a salt of nicotine and 3,5-dihydroxybenzoic acid, said form being a hydrated form characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2θ diffraction angles: 10.7, 13.4, 15.0, 17.2, 17.3, 19.0, 21.4, 21.6, 22.2, 22.6, 22.9, 24.3, 25.1, 25.5, and 29.
7.
6. 2. The nicotine salt or crystalline polymorphic form of claim 1, comprising a salt of nicotine and 2,3-dihydroxybenzoic acid, said form being characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2θ diffraction angles: 12.4, 12.5, 15.2, 18.3, 19.7, 20.3, 20.9, 24.9, 25.2, 26.5, and 30.
4.
7. 10. An electronic smoking article comprising an inhalable substance medium contained within a cartridge body and a heating member positioned to provide heat to at least a portion of the inhalable substance medium, wherein the inhalable substance medium comprises one or more of the nicotine salts or crystalline polymorphic forms described in claim 1.
8. The electronic smoking article of claim 7, wherein the inhalable substance medium further comprises one or more of glycerin, water, and flavoring materials.
9. 8. The electronic smoking article of claim 7, wherein the amount of nicotine salt or crystalline polymorphic form is sufficient to provide an amount of nicotine from about 0.01 mg to about 0.5 mg per puff of the article.
10. 8. The electronic smoking article of claim 7, wherein the amount of nicotine salt or crystalline polymorphic form is sufficient to provide an amount of nicotine from about 0.05 mg to about 0.3 mg per puff of the article.
11. 8. The electronic smoking article of claim 7, wherein the amount of nicotine salt or crystalline polymorphic form is sufficient to provide an amount of nicotine from about 0.1 mg to about 0.2 mg per puff of the article.
12. 13. A smokeless tobacco product comprising one or more of the nicotine salts or crystalline polymorphic forms of claim 1.
13. 13. The smokeless tobacco product of claim 12, selected from the group consisting of loose moist snuff (e.g., snus); loose dry snuff; chewing tobacco; pelletized tobacco pieces; extruded or formed tobacco strips, pieces, rods, cylinders, or sticks; finely divided powders; finely divided or pulverized agglomerates of powdered pieces and ingredients; flake-like pieces; molded tobacco pieces; gums; rolls of tape-like films; water-soluble or water-dispersible films or strips; meltable compositions; lozenges; drops; and capsule-like materials having an outer shell and an inner region.
14. 13. A pharmaceutical product comprising one or more of the nicotine salts or crystalline polymorphic forms of claim 1.
15. 15. The pharmaceutical product of claim 14, in a form selected from the group consisting of a pill, a tablet, a lozenge, a capsule, a caplet, a pouch, a gum, an inhalant, a solution, and a cream.
16. 10. A lozenge comprising one or more of the nicotine salts or crystalline polymorphic forms of claim 1 and at least about 50% by weight of isomalt.
Citation Information
Patent Citations
JP7726320B
Tobacco-tablet
US1376586A
Smokeless tobacco product
US20040020503A1
Wrapping materials for smoking articles
US20050016556A1
Smokable rod for a cigarette
US20050066986A1
